https://trial.medpath.com/news/1ad261eca3a8e607/fda-rejects-sotagliflozin-for-type-1-diabetes-with-ckd-following-negative-advisory-review 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e9a226804644526/xbrane-resubmits-ranibizumab-biosimilar-bla-to-fda-following-complete-response-letter 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/18c3cfc0a93fcf4c/cerebral-palsy-global-clinical-trials-review-2024-clinical-trials-by-region-country-trial-status-trial-phase-sponsor-type-and-end-point-status 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd795fd64bb9e22e/fda-revokes-authorization-of-drug-trump-touted-for-covid-19 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d183f24bbf112624/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical 2024-12-30T22:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/e70c5bdedea3fd65/agios-pharmaceuticals-advances-tebapivat-for-sickle-cell-disease-and-hemolytic-anemias 2024-12-30T21:59:35+00:00 weekly 0.7 https://trial.medpath.com/news/ffb6b2421c93bb66/nvp-healthcare-advances-oral-treatment-nvp-1805r2-for-cardiovascular-disorders 2024-12-30T21:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/412fd6e78a21328f/taiho-pharmaceutical-advances-tas-0728-a-novel-her2-her3-inhibitor-for-multiple-solid-tumors 2024-12-30T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/4db26f5c2b4af3ed/immedica-acquires-marinus-pharmaceuticals-for-151m-expanding-rare-disease-portfolio-with-ztalmy 2024-12-30T21:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/2b141b645b97eb93/fda-grants-priority-review-to-verastem-s-breakthrough-ovarian-cancer-treatment-vstm 2024-12-30T21:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/80725bd0d249dd2e/bria-imt-cancer-vaccine-shows-efficacy-tolerability-in-advanced-breast-cancer 2024-12-30T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/690062ea5f14a512/t-dxd-plus-pembrolizumab-elicits-responses-in-io-naive-her2-expressing-or-mutant-nsclc 2024-12-30T21:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/f9ccb70accee26ec/novel-car-t-cell-therapy-trial-advances-to-third-cohort-in-ovarian-cancer 2024-12-30T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/97d800ca140bf6ac/kymera-s-stat3-degrader-kt-333-shows-promise-across-multiple-lymphomas-and-solid-tumors 2024-12-30T19:54:15+00:00 weekly 0.7 https://trial.medpath.com/news/7fbc285da8510314/incyte-s-alk2-inhibitor-zilurgisertib-fumarate-shows-promise-across-multiple-hematologic-disorders 2024-12-30T19:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/da5780f524dbc50d/november-s-phase-iii-successes-syros-cassava-tumble-on-misses-bioworld 2024-12-30T19:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/4797060544f0281d/d-boral-capital-served-as-exclusive-placement-agent-to-fibrobiologics-inc-nasdaq 2024-12-30T19:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/ca280ef952812d7b/lumisystem-in-lumpectomy-may-reduce-or-omit-radiation-in-breast-cancer 2024-12-30T19:13:32+00:00 weekly 0.7 https://trial.medpath.com/news/4ea700d81c1ce41f/addition-of-pembrolizumab-to-chemo-improves-survival-in-cervical-cancer 2024-12-30T19:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/be0723753687bcca/takeda-s-oral-tyk2-inhibitor-zasocitinib-advances-development-for-multiple-autoimmune-conditions 2024-12-30T18:44:38+00:00 weekly 0.7 https://trial.medpath.com/news/1f37c6aad9700a8a/innocare-s-orelabrutinib-shows-promise-in-treating-primary-immune-thrombocytopenia 2024-12-30T18:42:55+00:00 weekly 0.7 https://trial.medpath.com/news/97379147dcc87ed5/neoadjuvant-anti-pd1-immunotherapy-for-surgically-accessible-recurrent-glioblastoma-nature 2024-12-30T18:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/e28b23d64d74937f/kala-bio-announces-10750000-private-placement-biospace 2024-12-30T18:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/00cec29fe713f996/behavioral-intervention-decreases-how-much-pain-affects-daily-activities-in-people-with 2024-12-30T17:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/32d87078d754ebeb/psca-targeted-bpx-601-car-t-cells-with-pharmacological-activation-by-rimiducid-in 2024-12-30T17:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/b0ee02bd6c9980ac/trivalent-recombinant-protein-vaccine-induces-cross-neutralization-against-xbb-lineage-and 2024-12-30T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/0bfccd53dbab17ad/nos-inhibition-sensitizes-metaplastic-breast-cancer-to-pi3k-inhibition-and-taxane-therapy-via 2024-12-30T17:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/cada94a7860c12b7/novartis-says-new-drug-helps-children-with-rare-spinal-condition 2024-12-30T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/317147f6867fbdda/phaxiam-therapeutics-presents-clinical-data-of-the-phagodair-pilot-study-with-results 2024-12-30T16:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/a1c8b4a15da4b05e/top-10-als-news-stories-of-2024 2024-12-30T16:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/00077d26bb17b252/top-10-news-stories-of-2024-on-rare-disease-angioedema 2024-12-30T16:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/2fba67c123af17bf/relative-effectiveness-of-antidepressant-treatments-in-treatment-resistant-depression-nature 2024-12-30T14:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/d3f3dea169b3c7d5/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-initial-section-of-u-s-new-drug 2024-12-30T14:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/834f923d228763b2/radiopharm-announces-strategic-co-development-partnership-with-lantheus-for-australia 2024-12-30T13:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/1b62d0a724c52cf0/determining-suitable-radioligand-therapy-use-in-neuroendocrine-tumors 2024-12-30T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/de10f0eabb8ac1ee/handok-secures-approval-for-itp-treatment-doptelet-kbr 2024-12-30T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/38643fbddacfc39a/accuracy-of-esat6-cfp10-skin-test-compared-with-tuberculin-skin-test-in-a-healthy-population 2024-12-30T12:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/fd813455ca060441/axsome-s-alzheimer-s-drug-shows-promise-in-trials-by-investing-com 2024-12-30T12:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/09ef7cb5659ccb3e/cspc-pharmaceutical-group-limited-s-leuprorelin-extended-release-injection-obtains 2024-12-30T12:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/ddd1679c5ccf5408/fda-grants-priority-review-to-precigen-s-prgn-2012-for-recurrent-respiratory-papillomatosis 2024-12-30T12:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/35c97ee341cc9179/boehringer-ingelheim-advances-vicadrostat-development-for-chronic-kidney-disease-and-heart-failure 2024-12-30T11:38:24+00:00 weekly 0.7 https://trial.medpath.com/news/05a36a36d0b2e7dd/nevada-king-gold-reports-significant-discoveries-and-outlines-ambitious-2025-drill-program-at-atlanta-gold-project 2024-12-30T11:33:32+00:00 weekly 0.7 https://trial.medpath.com/news/d380805aa666aeaa/engaging-fathers-to-be-a-pilot-study-on-the-adaptation-and-programme-experience-of 2024-12-30T10:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/fe9954ec9a59a094/leyden-labs-advances-novel-broad-spectrum-nasal-antibody-cr-9114-against-multiple-influenza-strains 2024-12-30T10:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/d635f4fc99f6ce23/innovation-pharmaceuticals-brilacidin-shows-promise-across-multiple-therapeutic-areas 2024-12-30T10:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/c700e7db856b5d88/new-schizophrenia-drug-may-have-milder-side-effects-word-in-black 2024-12-30T10:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/ec31a17fc855ca9c/roche-s-tecentriq-atezolizumab-expands-development-program-into-squamous-non-small-cell-lung-cancer 2024-12-30T10:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/4b061992d6799304/the-efficacy-of-longer-term-lebrikizumab-treatment-in-patients-with-moderate-to-severe-pubmed 2024-12-30T09:48:54+00:00 weekly 0.7 https://trial.medpath.com/news/3b021eec52436f36/mayo-clinic-s-e-visit-billing-program-shows-8-8-reduction-in-patient-portal-messages 2024-12-30T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/70f9bbe9b316b950/2024-marks-a-turning-point-in-weight-loss-for-floridians-with-anti-obesity-medications 2024-12-30T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/04c31a634659cb8f/european-commission-approves-rybrevant-r-amivantamab-in-globenewswire 2024-12-30T08:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/9696ce5a6c5f1673/top-10-healthcare-news-in-2024-7-yuhan-s-leclaza-makes-us-entry-to-become-a-global 2024-12-30T07:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/2d4600263a0ec788/participation-and-compliance-in-a-multimodal-prehabilitation-program-f-ppa 2024-12-30T07:29:42+00:00 weekly 0.7 https://trial.medpath.com/news/e97cbee126a1a4db/study-reveals-significant-gap-between-pah-patient-and-physician-symptom-assessment 2024-12-30T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/137f6fd0ecf65d4f/mayo-clinic-s-dr-rafael-fonseca-pioneering-multiple-myeloma-research-and-treatment-revolution 2024-12-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b0d34e062366d69/critical-drug-shortages-persist-in-2024-despite-overall-decline-in-supply-disruptions 2024-12-30T05:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/60e61e002c207f45/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-globenewswire 2024-12-30T05:46:02+00:00 weekly 0.7 https://trial.medpath.com/news/7f74226a6ad13124/key-research-advances-in-mds-treatment-and-risk-assessment-2024-s-most-impactful-studies 2024-12-30T05:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/d077cf8bb35c951e/zorifer-poised-to-fill-critical-gap-in-treatment-of-advanced-nsclc-with-cns-metastases-in 2024-12-30T05:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/c881a36c8fde7184/ruxolitinib-cream-shows-promise-in-pediatric-atopic-dermatitis-and-vitiligo-treatment-spd-2024-findings 2024-12-30T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd828c7c99594404/340b-drug-program-faces-scrutiny-over-hospital-markups-and-transparency-issues-in-cancer-care 2024-12-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e235102853647728/abion-s-c-met-targeted-anticancer-drug-phase-2-change-approved-by-fda-lazertinib 2024-12-30T04:47:24+00:00 weekly 0.7 https://trial.medpath.com/news/db358892e67da9d8/vincerx-pharma-enters-into-a-binding-term-sheet-for-a-strategic-merger-with-oqory-inc 2024-12-30T04:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/01315ef470788ab9/vor-bio-announces-55-6-million-private-placement-biospace 2024-12-30T04:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/13773b59f079a952/yoltech-therapeutics-granted-fda-orphan-drug-and-rare-pediatric-disease-designations 2024-12-30T04:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/6c65108ebe1b4add/immune-biomarkers-show-promise-in-guiding-tnbc-treatment-decisions 2024-12-30T04:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/87ebe953f33edc27/carsgen-reports-positive-trial-results-for-cancer-therapy-markets-insider 2024-12-30T03:22:49+00:00 weekly 0.7 https://trial.medpath.com/news/fbd019d837c3baba/digital-biomarkers-revolutionize-respiratory-disease-management-new-hope-for-copd-and-asthma-patients 2024-12-30T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6c5da74658c2f850/kintor-s-phase-iii-trial-milestone-for-hair-loss-treatment-tipranks-com 2024-12-30T00:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/e3049feb07f93e3f/cgtlive-s-2024-pillars-of-progress-top-news-in-ophthalmology 2024-12-30T00:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/1ecf7a62e4ff12dd/breakthroughs-in-bladder-cancer-treatment-highlighted-in-2024 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd6ada87779db7d5/italian-multicenter-trial-evaluates-lifestyle-intervention-for-long-term-lymphoma-survivors 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3878771b99301a2b/novartis-expands-car-t-therapy-kymriah-s-use-in-europe-outpacing-gilead-s-rival 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8e36158a86bfc4c4/exscientia-claims-world-first-as-ai-created-drug-enters-clinic 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6df00adb218415a1/covid-19-pipeline-insights-clinical-trials-treatment-drugs-and-companies-2024-updated 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3eb0803138248f4d/slrn-stock-touches-52-week-low-at-3-06-amid-market-challenges-by-investing-com 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/39fe4dc555da4808/neurologylive-r-year-in-review-2024-top-stories-in-multiple-sclerosis 2024-12-29T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/e31df2be3ecb41ae/new-study-highlights-ai-s-role-in-stimulating-thought-caliber-az 2024-12-29T22:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/e04e653bdeea91b4/telix-files-tlx250-cdx-zircaix-r-bla-for-kidney-cancer-imaging-globenewswire 2024-12-29T21:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/7145e8e818bb437c/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-cancer-immunotherapy 2024-12-29T19:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/799e45e1f525622b/jaaf-gtex-drive-sl-s-textile-innovation-and-competitiveness-daily-mirror 2024-12-29T19:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/912fa8eb2f2aec3c/breakthroughs-and-battles-in-health-new-approvals-lawsuits-and-discoveries 2024-12-29T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/b3a992d4c3df9b36/top-10-kidney-cancer-stories-in-2024 2024-12-29T17:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/c15884be08fafde6/2024-veterinary-news-in-review-3-dvm360 2024-12-29T16:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/3f0edb9f482f0bd9/second-line-lenvatinib-shows-promising-pfs-in-advanced-hcc-oncology-nursing-news 2024-12-29T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/be1d132fa18bcf3e/ivonescimab-chemo-combo-yields-positive-efficacy-and-safety-results-in-tnbc 2024-12-29T15:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/a6dfc6870c05fc69/a-randomized-trial-of-low-dose-thrombolysis-ultrasound-assisted-thrombolysis-or-heparin 2024-12-29T15:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/01a4063312676a27/have-the-new-pulmonary-hypertension-drugs-changed-the-game-medpage-today 2024-12-29T14:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/c3d6e024011699bf/neurologylive-r-year-in-review-2024-top-stories-in-movement-disorders 2024-12-29T13:55:31+00:00 weekly 0.7 https://trial.medpath.com/news/c5068bef9277824e/ideaya-biosciences-secures-exclusive-license-for-novel-cancer-treatment-gurufocus 2024-12-29T12:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/48410551c598b7b3/io-biotech-faces-possible-nasdaq-delisting-over-low-stock-price 2024-12-29T12:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/35f96ddbdf5e1975/aoh1996-targets-mitochondrial-dynamics-and-metabolism-in-leukemic-stem-cells-via 2024-12-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/50fc68b637c9a41d/short-interest-in-adlai-nortye-ltd-nasdaq-anl-increases-by-28-0-marketbeat 2024-12-29T10:44:04+00:00 weekly 0.7 https://trial.medpath.com/news/09bc2bbead891bce/bio-path-holdings-advances-clinical-trials-and-secures-4-million-in-funding-citybuzz 2024-12-29T10:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/d60b185791b6bb97/fda-approvals-and-treatment-advances-mark-major-progress-in-pah-management-for-2024 2024-12-29T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/e428ed5af85098ed/leading-mds-expert-dr-garcia-manero-reflects-on-25-years-of-mentorship-and-innovation-at-md-anderson 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d58e96bf7ad72bf/early-detection-through-symptom-based-testing-shows-promise-in-ovarian-cancer-diagnosis 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d4a7279ff200154/telehealth-proves-vital-for-rare-disease-management-post-pandemic-breaking-healthcare-access-barriers 2024-12-29T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa953db89c80a64a/expert-insights-keys-to-successfully-transitioning-from-hematology-oncology-fellow-to-attending-physician 2024-12-29T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/08aa19b22b7f49a5/dermatology-times-2024-in-review-hidradenitis-suppurativa 2024-12-29T02:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/0e359411494aad04/biocardia-s-short-interest-declines-19-5-as-analysts-maintain-bullish-outlook 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/afc827e6e9799c64/novel-nk-cell-therapy-myj-1633-shows-promise-for-multiple-cancer-types-including-her2-breast-cancer 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8aff45106cf62c3/top-10-prostate-cancer-articles-and-videos-of-2024-urology-times 2024-12-28T23:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/d14dadfa21e07f56/neurologylive-r-year-in-review-2024-top-stories-in-headache-and-migraine 2024-12-28T22:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/ffbfcea8697d673f/new-pill-that-slows-down-alzheimer-s-being-considered-for-use-by-nhs-daily-express 2024-12-28T21:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/9df15d5c30d1a464/2024-brings-change-new-hope-for-nonhormonal-management-of-menopause-hcplive 2024-12-28T19:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/067eccb0e1efa67a/contagion-s-2024-top-stories-c-difficile 2024-12-28T19:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/ff470d032e0963f0/iqvia-gets-cdsco-panel-nod-to-conduct-phase-iii-clinical-study-of-lumateperone 2024-12-28T17:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/5d728fceb04b1623/zanidatamab-evorpacept-combo-yields-promising-activity-in-her2-breast-cancer 2024-12-28T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/3a4bccedd5042c20/china-developed-eye-cancer-drug-granted-fda-orphan-drug-designation 2024-12-28T16:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/39cb9c6682601b39/who-wants-a-pig-organ-patients-sick-and-tired-of-waiting-years-for-a-transplant-health 2024-12-28T16:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/05b8c41b0a225dff/top-endovascular-news-of-2024-tctmd-com 2024-12-28T14:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/a42ced4184da9840/cruise-ships-and-norovirus-don-t-mix-vax-before-travel 2024-12-28T14:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/e1ef9b3bf0d31892/faricimab-lacks-proof-of-added-benefit-over-comparator-therapies-for-macular-edema 2024-12-28T14:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/6961ca0e733cea45/vaxart-secures-additional-4-6-m-for-covid-19-pill-vaccine-trial-investing-com-nigeria 2024-12-28T13:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/9b8169a9f82f25f9/probiotic-treatment-induces-changes-in-intestinal-microbiota-but-does-not-alter-scfa-levels 2024-12-28T13:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/86af794e8bcea49c/fmba-has-begun-clinical-trials-of-a-vaccine-against-five-serotypes-of-meningococcus-news 2024-12-28T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/1148668a69aeac2e/earliest-clinical-trial-for-vco-to-end-in-december-next-year-for-avigan-doh-abs-cbn 2024-12-28T11:57:06+00:00 weekly 0.7 https://trial.medpath.com/news/6edcad2f393d1942/evaluation-of-vascular-photobiomodulation-for-orofacial-pain-and-tension-type-headache 2024-12-28T11:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/d9f19c28638a9564/top-10-genitourinary-cancer-advances-in-2024-targeted-oncology 2024-12-28T10:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/c4e777d20cbfc80e/breakthrough-in-chronic-hand-eczema-treatment-tofacitinib-shows-promising-results 2024-12-28T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/592d3b3093ce1d58/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors-onclive 2024-12-28T08:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/d46e9e83a750bac4/clinically-validated-classification-of-chronic-wounds-method-with-memristor-based-cellular 2024-12-28T08:26:40+00:00 weekly 0.7 https://trial.medpath.com/news/6b896828bc8c9807/headway-in-hepatology-resmetirom-s-historic-fda-approval-what-s-next-in-mash 2024-12-28T07:43:35+00:00 weekly 0.7 https://trial.medpath.com/news/d378094a6ef58cde/2024-rsv-vaccination-guidelines-strengthen-recommendations-for-adults-75-and-older 2024-12-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ce51e96ca14747c/dr-carol-aghajanian-pioneering-patient-centric-innovation-in-gynecologic-cancer-treatment 2024-12-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc2f98c441f9c387/ai-powered-tool-predicts-treatment-outcomes-for-brain-metastases-following-radiosurgery 2024-12-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8654159c1b06451/inside-the-battle-for-fda-approval-of-mdma-therapy-big-think 2024-12-28T03:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/1186d39ddaac21e5/mezigdomide-combinations-show-promise-in-multiple-myeloma-medpage-today 2024-12-28T03:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/83a99febdd0c95a6/top-5-articles-in-2024-for-oncology-apps-and-nurses 2024-12-28T03:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/8bddf9a00c91ab2e/study-reveals-gap-in-community-practice-training-for-hematology-oncology-fellows 2024-12-28T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d1888343639e27ac/greg-forlenza-md-discusses-clver-trial-among-newly-diagnosed-type-1-diabetes-patients 2024-12-28T02:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/c10aa13ec77afdac/fda-roundup-december-27-2024-pr-newswire 2024-12-28T02:32:53+00:00 weekly 0.7 https://trial.medpath.com/news/47e5cf23d5510a2d/frontiers-comparative-efficacy-of-different-drugs-in-acute-heart-failure-with-renal-dysfunction 2024-12-28T02:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/b5cbc15621e48528/mixed-evidence-on-glp-1-medications-and-suicide-risk-a-2024-safety-analysis-review 2024-12-28T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e9d544f1889405d/optimizing-the-cumulative-cisplatin-dose-for-concurrent-chemoradiotherapy-beneficiaries 2024-12-28T01:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/4309eba01d767c8a/a-randomised-controlled-pilot-trial-protocol-for-patient-led-cognitive-gamified-training-during 2024-12-28T01:35:18+00:00 weekly 0.7 https://trial.medpath.com/news/b29a57427b48beda/eqbmed-broadens-reach-final-four-clinical-trial-sites-of-the-learning-phase-selected 2024-12-28T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/5b9c60efa611a61e/bristol-myers-squibb-receives-fda-approval-for-cancer-treatment-marketwatch 2024-12-27T23:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/c8970518e904d684/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides 2024-12-27T22:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/3fab70dbd994d6e5/us-fda-approves-subcutaneous-opdivo-extending-key-bms-franchise-into-2030s 2024-12-27T21:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/d073b28fa83b6974/nebraska-medicine-administers-novel-gene-therapy-to-first-hemophilia-patient 2024-12-27T21:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/68de0414e42e46b6/ebola-how-a-vaccine-turned-a-terrifying-virus-into-a-preventable-disease-cnn 2024-12-27T20:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/616dd82735a6c932/neoadjuvant-pembrolizumab-plus-rt-may-enhance-dfs-outcomes-in-sarcomas 2024-12-27T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/8bb8edbc8026a868/ema-s-chmp-recommends-approval-of-six-new-biosimilars-goodwin-jdsupra 2024-12-27T17:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/022da8e96a25b062/top-5-most-viewed-liver-cancer-content-for-2024 2024-12-27T17:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/17dac7cddfdbc573/puma-biotechnology-stock-rises-24-in-3-months-here-s-why-yahoo-finance 2024-12-27T17:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/04410fd4ecadbe5c/what-awaits-actinium-in-q4 2024-12-27T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/814b519ac3020c6d/sino-biopharmaceutical-limited-announces-positive-results-from-phase-iii-study-marketscreener 2024-12-27T16:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/8ba9b32a2c81367a/avacta-group-advances-oncology-pipeline-with-novel-therapies-and-ai-collaboration 2024-12-27T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/ea83f1e8a58afc67/changes-in-gut-microbiota-after-gastric-cancer-surgery-a-prospective-longitudinal-study 2024-12-27T15:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/a8594297902585c7/5-major-alzheimer-s-discoveries-scientists-made-in-2024-aol-com 2024-12-27T15:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/fc1eb24c276e0ced/ucsd-researchers-clinically-validate-blood-pressure-monitoring-patch 2024-12-27T15:38:06+00:00 weekly 0.7 https://trial.medpath.com/news/f9bbaa1304078210/top-10-food-allergy-stories-of-2024-healio 2024-12-27T15:18:33+00:00 weekly 0.7 https://trial.medpath.com/news/9ee7903de565640d/cardiol-therapeutics-sees-insider-buying-from-leadership-team-and-board-members 2024-12-27T15:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/ad78a19cafd4e568/decentralized-clinical-trials-are-better-for-the-participants-and-for-the-planet-the-case-study 2024-12-27T14:55:27+00:00 weekly 0.7 https://trial.medpath.com/news/0bc729111baa4d6d/cereno-scientific-has-enrolled-9-additional-patients-in-its-expanded-access-program-cision-news 2024-12-27T14:38:16+00:00 weekly 0.7 https://trial.medpath.com/news/05d630938b6f5529/cbd-may-reduce-alcohol-cravings-in-people-with-aud-study-finds-forbes 2024-12-27T14:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/c2f334b1b7504b5b/painreform-provides-further-update-on-phase-3-clinical-trial-of-prf-110-globenewswire 2024-12-27T13:56:29+00:00 weekly 0.7 https://trial.medpath.com/news/87b8cd5cbb9f71fe/outlook-therapeutics-r-reports-financial-results-for-fiscal-year-2024-and-provides 2024-12-27T13:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/643aa5f888ae5476/top-mesothelioma-and-asbestos-news-in-2024 2024-12-27T12:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/3ef63281d8770edb/feasibility-study-and-pilot-rct-on-tourniquet-use-in-total-knee-replacement-surgery 2024-12-27T12:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/f6c64e3d3505fdc0/in-kids-with-crohn-s-disease-tnf-inhibitors-help-prevent-serious-complications-data-suggests 2024-12-27T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/9eba0d683acd0ae5/chugai-obtains-regulatory-approval-for-lunsumio-for-intravenous-infusion-for-relapsed 2024-12-27T12:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/e3e2ef0b1d1cbbcf/enrolment-patterns-in-a-randomized-controlled-trial-of-probiotics-in-critically-ill-patients 2024-12-27T11:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/1a9682e8425f1bf6/fda-approves-tevimbra-chemotherapy-combination-for-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma 2024-12-27T11:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/37b0d8ba90f9a2a0/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-in 2024-12-27T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/12e1daeb7ce58107/sensorion-announces-completion-of-enrollment-of-the-first-cohort-of-the-audiogene-biospace 2024-12-27T10:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/845033b38fe54291/relapsed-multiple-myeloma-clinical-trials-review-2024-globenewswire 2024-12-27T09:36:56+00:00 weekly 0.7 https://trial.medpath.com/news/75262e87e9464e23/dengue-fever-global-clinical-trials-review-2024-globenewswire 2024-12-27T09:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/acb32a72c68ce964/updated-colonoscopy-guidelines-reshape-quality-metrics-as-family-physician-procedures-decline 2024-12-27T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf2e9e057003ac05/ono-receives-supplemental-approval-of-opdivo-r-in-combination-with-cisplatin-and 2024-12-27T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/1a741c57029c512e/alto-neuroscience-presents-key-data-study-findings-on-alto-300-psychiatric-times 2024-12-27T08:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/f0fca7a4a0352061/pioneer-in-genitourinary-oncology-dr-christopher-logothetis-s-journey-from-greece-to-revolutionizing-cancer-care 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56dffb801bd270fb/novel-ruxolitinib-dosing-strategy-shows-promise-in-managing-anemic-myelofibrosis-patients 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3b8e2c50670ba77/a-domestic-drug-for-one-type-of-cancer-has-been-registered-in-russia-oreanda-news 2024-12-27T07:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/0ed2b5577074812b/radiation-oncology-pioneer-ralph-weichselbaum-named-2024-giants-of-cancer-care-inductee 2024-12-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dfd9a09c3a778a27/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-biospace 2024-12-27T05:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/564e426c6712286a/breakthrough-developments-in-waldenstrom-macroglobulinemia-treatment-btk-inhibitors-and-novel-therapies-show-promise 2024-12-27T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/121bd7236cc5325e/exicure-inc-partners-with-gpcr-therapeutics-to-fuel-new-growth-in-biotech-stock-titan 2024-12-27T03:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/c713c85925c6088a/sbrt-plus-sorafenib-boosts-os-over-sorafenib-alone-for-hcc-docwire-news 2024-12-27T01:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/48f22f0ff3d145c5/enterprise-generative-ai-in-pharma-navigating-cautious-adoption-for-transformative-impact 2024-12-27T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e0503c8015341c2/breakthrough-study-identifies-five-distinct-alzheimer-s-subtypes-paving-way-for-personalized-treatment 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7bdda93ceb06cc58/immupharma-lon-imm-trading-down-7-3-here-s-why 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe3f20c3ee9e645c/tumor-mutational-burden-may-guide-treatment-in-metastatic-breast-cancer 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b041be5205283dfc/madrigal-pharmaceuticals-advances-in-nash-treatment-with-resmetirom-phase-3-trials 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1feecd679637916b/fda-advances-in-ophthalmology-2024-highlights 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/25fbd45a3d1dc9fd/innate-pharma-unveils-growth-strategy-and-highlights-clinical-trial-progress 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed2656930143e51d/adhd-medication-shows-promise-in-treating-methamphetamine-dependence 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ccaedc3936c37e4/recent-advances-in-medical-treatments-and-regulatory-approvals 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b194c48c096c430/rpt193-drug-hunter 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b27c5fe1a5e14446/viracta-therapeutics-announces-closure-of-naval-1-clinical-globenewswire 2024-12-26T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/b859621c18bc3c63/psychedelic-alpha-s-top-11-stories-from-2024 2024-12-26T21:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/fdbf4f76eff7f446/cardiology-year-in-review-2024-hcplive 2024-12-26T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/de658c30ab7ce6a3/tislelizumab-triplet-shows-meaningful-responses-pfs-in-metastatic-tnbc 2024-12-26T21:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/6766e56bc64dc28f/sermonix-and-henlius-dose-first-chinese-patient-in-phase-3-globenewswire 2024-12-26T20:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/f0e6919851c0fa7d/ohtuvayre-from-verona-pharma-pharmacy-times 2024-12-26T20:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/0a697feae6702a25/tirzepatide-may-increase-aes-in-hr-her2-breast-cancer-treatment 2024-12-26T19:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/a99e90fe97bc9a5e/cardiology-most-read-stories-from-2024-drug-topics 2024-12-26T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/2eaa5b272077a0e5/preliminary-evidence-of-renal-function-improvement-newswise 2024-12-26T17:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/bcf9587606ee38db/the-affects-of-env-101-on-ipf-pharmaceutical-executive 2024-12-26T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/43d7d16d1ae2523c/vertex-pharmaceuticals-stock-is-down-13-here-s-why-you-should-buy-the-dip 2024-12-26T16:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/28bfd84cd6abea64/pharma-stock-roundup-nvo-s-obesity-study-failure-fda-nod-to-pfe-lly-barchart-com 2024-12-26T16:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/705c5c5e2020b88f/top-5-stories-from-the-2024-san-antonio-breast-cancer-symposium-cure-today 2024-12-26T16:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/c727ba1758cb54ac/immunogenicity-reactogenicity-and-safety-of-a-pentavalent-meningococcal-abcwy-pubmed 2024-12-26T15:58:26+00:00 weekly 0.7 https://trial.medpath.com/news/ff1ffa8acfe2e6f2/os-therapies-partners-with-b2i-digital-to-engage-with-biotech-investors-online-stock-titan 2024-12-26T15:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/8c073a6d432e550d/rx-road-map-erdafitinib-balversa-oncology-nursing-news 2024-12-26T15:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/944cc4d0d110a03b/effect-of-individualized-versus-conventional-perioperative-blood-pressure-management-on-trials 2024-12-26T14:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/8e1aa3ed131c2ad7/casi-pharmaceuticals-faces-clinical-hold-on-cid-103-by-fda-tipranks-com 2024-12-26T14:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/947798cbc5173e1d/assembly-biosciences-reports-interim-phase-1b-results-from-clinical-trial-evaluating-next 2024-12-26T13:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/d728241d43aaeed8/the-chase-for-novel-oral-glp-1-obesity-meds-adds-a-new-contender-medcity-news 2024-12-26T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/62466f8f64d5fd31/managing-young-mpn-patients-balancing-long-term-treatment-risks-and-benefits 2024-12-26T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/3fc25bc7a01db37b/palvella-therapeutics-stock-gains-attention-with-phase-3-trial-data-expected-in-early-2026 2024-12-26T12:23:31+00:00 weekly 0.7 https://trial.medpath.com/news/757c9c09381302af/polypid-stock-poised-for-2026-launch-despite-adjusted-target-from-hc-wainwright 2024-12-26T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/8cbd678bf1bdbee6/genomic-scarring-score-predicts-the-response-to-parp-inhibitors-in-non-small-cell-lung-cancer 2024-12-26T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/1529220e1f3f726d/neurologylive-r-year-in-review-2024-top-conference-coverage-stories 2024-12-26T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/93f8c0749743792a/microtech-announces-first-human-case-of-implantable-microsensor-for-heart-failure 2024-12-26T11:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/19565b5f67f0ade7/ind-application-for-a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous 2024-12-26T09:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/78b4129d55abc7e6/dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-global-clinical-trials-review-2024 2024-12-26T09:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/57639e25218be471/fda-mandates-standardized-asbestos-testing-protocol-for-talc-based-cosmetics 2024-12-26T09:33:31+00:00 weekly 0.7 https://trial.medpath.com/news/a41a58c104c62c2f/tiumbio-s-hemophilia-novel-drug-candidate-tu7710-achieves-successful-results-in-phase 2024-12-26T07:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/4fbbcd6addeb70ec/novel-research-reveals-uchl1-as-therapeutic-target-in-ovarian-cancer-and-western-diet-s-impact-on-liver-cancer 2024-12-26T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d44c431beb30b50/real-world-data-validates-venetoclax-s-efficacy-in-cll-patients-after-btk-inhibitor-treatment 2024-12-26T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f70693f4279fb46/georgetown-oncologist-dr-john-marshall-s-journey-from-personal-loss-to-pioneering-gi-cancer-care 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f3b814fbc662f56/key-copd-research-highlights-mortality-risks-treatment-effects-and-biomarkers-in-2024 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9b9f2473223190a/pharmacy-prescribing-trials-provide-access-to-immediate-care-hmri 2024-12-26T05:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/30756eeeaa930d73/rxrx-stock-surges-with-promising-trials-whats-next-for-investors 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f499fabe42db53f1/telisotuzumab-vedotin-shows-promise-in-treating-c-met-positive-non-small-cell-lung-cancer 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/05cc7f61e1c9000e/systemic-sclerosis-clinical-trials-2024-ema-pdma-fda 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/19d630ae8dccef7a/lirodegimod-drug-targets-indications-patents 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cfa568d138b79cc0/novel-emotional-therapy-shows-superior-pain-reduction-in-veterans-compared-to-cbt 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/811e526cf3867ad9/merck-s-keytruda-faces-new-competition-in-cancer-treatment-arena 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/26505ee646e50d64/automated-insulin-delivery-systems-enhance-glycaemic-control-in-youth-with-type-1-diabetes 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/e056fcb135dd0e7c/xanomeline-trospium-chloride-first-approval-springermedicine-com 2024-12-25T23:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/c740f18746ffb459/gecacitinib-demonstrates-safety-efficacy-over-hydroxyurea-in-patients-with-myelofibrosis 2024-12-25T23:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/296e8a1e5e4b8eb8/top-5-cancer-vaccine-stories-from-2024-cure-today 2024-12-25T19:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/9efad24c320374b0/ozempic-for-alzheimer-s-what-drives-brain-age-primary-care-alzheimer-s-guideline 2024-12-25T18:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/8fd999ed3ad6db4a/biosimilar-market-achieves-major-breakthrough-in-2024-with-61-fda-approvals-and-12-4b-in-healthcare-savings 2024-12-25T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8b7d6e9e4f51e66/preliminary-results-of-qilu-pharmaceutical-s-phase-ia-study-on-gprc5d-cd3-targeting 2024-12-25T16:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/7558456357085c83/transcranial-magnetic-stimulation-for-teenage-depression-psychology-today 2024-12-25T15:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/6ab92b6fc71405ac/ropeginterferon-alfa-2b-response-improves-with-nfkb1-haplotype-in-pv-and-et 2024-12-25T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/29b05acefc6d335c/optimizing-infusion-chair-time-for-oncology-trials-follow-up-study 2024-12-25T14:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/279f4d9064812e50/stem-cell-therapy-offers-new-hope-for-children-with-heart-failure 2024-12-25T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/3eac150604db5946/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal-onclive 2024-12-25T13:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/a52922ddec85385e/precision-trial-hcplive 2024-12-25T13:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/c4ffd490f04c42a2/transformative-or-transitional-deciphering-the-role-of-niagara-in-shaping-future-practice 2024-12-25T12:59:35+00:00 weekly 0.7 https://trial.medpath.com/news/a6dbb8f85f2b61e1/medmira-receives-health-canada-approval-for-its-multiplo-r-rapid-tp-hiv-test-for 2024-12-25T12:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/18d1ce01c9a2cd94/imcivree-label-expanded-weight-loss-with-weekly-injection-kidney-donation-chain 2024-12-25T11:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/0a4246ac7b89fe1f/dreamm-11-part-2-japanese-phase-i-trial-of-belantamab-mafodotin-combination-therapies 2024-12-25T09:50:18+00:00 weekly 0.7 https://trial.medpath.com/news/425c0ce1b4c39f09/mass-balance-recovery-absorption-metabolism-and-excretion-of-elinzanetant-in-healthy 2024-12-25T09:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/10118f6359439e44/samsung-bioepis-advances-denosumab-biosimilar-sb16-for-osteoporosis-and-oncology-indications 2024-12-25T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/ef81e4753c681e61/mindmed-stock-skyrockets-94-year-to-date-what-s-driving-it-yahoo-finance 2024-12-25T08:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/d8d0964e5ca48707/ultragenyx-shares-retain-buy-rating-as-pivotal-phase-3-aspire-study-begins-for-angelman-syndrome 2024-12-25T06:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/676276ba9b4c8155/statin-therapy-shows-significant-cardiovascular-risk-reduction-in-elderly-patients-over-75 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed1a75047d673d27/novel-integrated-palliative-care-training-program-shows-promise-for-hematology-oncology-fellows 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe9a7131e8d0c057/brain-foundation-issues-rfp-research-to-benefit-individuals-with-autism-rfps-pnd 2024-12-25T05:21:24+00:00 weekly 0.7 https://trial.medpath.com/news/bcc0ea11ed667523/top-healthcare-experts-share-insights-on-obesity-management-primary-care-innovation-and-health-equity-in-2024-ivbm-coverage 2024-12-25T03:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/d7a9a4faac577bb4/castle-biosciences-reports-preliminary-data-from-atopic-dermatitis-test-study 2024-12-25T02:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/4fd6e730900a1c6a/basilea-receives-additional-funding-from-carb-x-to-advance-antibiotic-candidate 2024-12-25T00:35:24+00:00 weekly 0.7 https://trial.medpath.com/news/98a05b74d01c29b0/boehringer-ingelheim-partners-with-walgreens-for-obesity-and-diabetes-clinical-trial 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e8d6eac6480e4080/ustekinumab-biosimilar-by-celltrion-for-psoriatic-arthritis-likelihood 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ef5e3d1a18072883/cd20-bispecific-antibodies-show-promise-in-lymphoma-treatment-at-ash 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b0c1a3635d558e2c/fda-says-decongestant-in-many-cold-medicines-doesn-t-work-so-what-does-fox-13-memphis 2024-12-24T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/5874200eeb00f9d6/guess-which-asx-healthcare-stock-is-jumping-7-on-us-fda-approval-news-motley-fool 2024-12-24T22:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/fbb67c67daae1628/new-smartphone-app-successfully-treats-tinnitus-in-clinical-trial-the-brighter-side-of-news 2024-12-24T21:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/f2b7bce063f64bca/autologous-tumor-lysate-loaded-dendritic-cell-vaccination-in-glioblastoma-patients 2024-12-24T21:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/30c892682f8d8ded/new-ptsd-treatment-shows-promise-with-brexpiprazole-sertraline-combination 2024-12-24T19:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/cc028e03d8a999fb/mariposa-trial-shows-pfs-benefit-with-or-without-cns-disease-in-nsclc 2024-12-24T19:31:14+00:00 weekly 0.7 https://trial.medpath.com/news/7b6ac9554b8e87c7/prophylactic-approaches-lessen-immune-related-reactions-in-nsclc-cancer-network 2024-12-24T19:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/49c35cb747906e7b/fda-approves-flurry-of-drugs-ahead-of-holiday-season-pharmaphorum 2024-12-24T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/a8bd468f4b08b1c0/research-supports-need-for-diversity-in-hemophilia-trials-and-reducing-resource-strain 2024-12-24T18:42:19+00:00 weekly 0.7 https://trial.medpath.com/news/530ad7b17a983a70/journey-medical-corporation-announces-fda-approval-of-emrositm-for-rosacea-treatment 2024-12-24T18:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6def42e62060e07/where-do-psychedelics-fit-in-the-future-of-psychiatry-psychiatric-times 2024-12-24T18:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/acbbe02b2b5ed7cb/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial-stock-titan 2024-12-24T17:58:57+00:00 weekly 0.7 https://trial.medpath.com/news/38c51d2a00082598/innovation-collaboration-and-performance-were-highlights-for-ema-in-2024-pharmtech 2024-12-24T17:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/abd5ada7812c532b/progress-of-immune-checkpoint-inhibitors-therapy-for-pmmr-mss-metastat-ott 2024-12-24T17:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/851ef8bbd06444be/biocon-zentiva-get-eu-approval-for-generic-diabetes-weight-management-drug-the-hindu 2024-12-24T17:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/68e0d47530ef5839/hospitals-trial-ai-to-spot-type-2-diabetes-risk-bbc 2024-12-24T15:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/7805e75ee5928400/ractigen-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-for-rag-17-in 2024-12-24T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/a9ef71ce436fd598/os-therapies-announces-pricing-of-6-million-private-placement-stock-titan 2024-12-24T14:45:35+00:00 weekly 0.7 https://trial.medpath.com/news/4015f2f553a68d99/pfizer-launched-phase-3-trial-for-ibuzatrelvir-new-oral-antiviral-for-covid-19-treatment 2024-12-24T14:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/f98083687315b2ec/new-developments-in-car-t-treatments-webinar-series-summary-cancer-network 2024-12-24T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/6001fabc2e60a1a3/enanta-pharmaceuticals-stock-remains-buy-rated-with-phase-2-data-driving-model-revisions 2024-12-24T14:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/f4dde6c16cdd2ce0/novel-radiogenomics-approach-to-predict-and-characterize-pneumonitis-in-stage-iii-nsclc 2024-12-24T13:51:48+00:00 weekly 0.7 https://trial.medpath.com/news/fe02a0016967cdc3/precision-pathways-targeted-therapies-mutation-driven-treatment-strategies 2024-12-24T13:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/a6a207efb8b59807/2-year-results-from-an-observational-study-of-proactive-treatment-regimens-with-intravitreal-nature 2024-12-24T12:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/a9da2925dcdb583e/biocon-shares-ascend-5-as-company-receives-approval-for-diabetes-drug-in-eu-upstox 2024-12-24T11:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/cf15db453a58d1ee/meta-analysis-reveals-shingles-infection-significantly-increases-risk-of-parkinson-s-and-dementia 2024-12-24T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6da33d91b96d0b9/hanmi-pharm-seeks-approval-for-triple-combination-hypertension-drug-pharma-article-kbr 2024-12-24T11:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/581306640d568d37/pyelonephritis-global-clinical-trials-review-2024-yahoo-finance 2024-12-24T09:19:50+00:00 weekly 0.7 https://trial.medpath.com/news/c2df51fb7606cbe4/study-reveals-high-frequency-of-ivig-related-adverse-events-in-pediatric-patients 2024-12-24T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e36e2b7089dd5bd9/fda-boosts-vaccine-development-amid-egg-recall-crisis-the-pinnacle-gazette 2024-12-24T08:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/50562dc98fe3bb44/caqh-ceo-highlights-hidden-costs-and-care-gaps-in-women-s-menopausal-health 2024-12-24T08:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/d3333c0df1a990a2/the-novel-bispecific-antibody-ivonescimab-may-be-poised-to-change-the-soc-in-nsclc 2024-12-24T08:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/3c6386fcdf8020d2/nature-cell-seeks-fda-meeting-for-arthritis-therapy-approval-kbr 2024-12-24T08:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/1d155df6bcb61c34/astrazeneca-withdraws-eu-application-for-lung-cancer-drug-tipranks-com 2024-12-24T07:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/5580bef8ca3e46a2/anavex-life-sciences-corp-avxl-q4-2024-earnings-call-highlights-strong-cash-position-and 2024-12-24T07:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/cbccb4b0f28ee64e/ribociclib-combo-may-provide-benefit-to-certain-breast-cancer-subtypes-oncology-nursing-news 2024-12-24T07:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/51ec5821bafe0c54/study-calls-for-optimization-of-high-cost-ivig-therapy-in-bk-nephropathy-treatment 2024-12-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9cca74da54dab230/clinical-trial-digitalization-transforms-drug-development-ai-remote-monitoring-and-data-ecosystems-lead-innovation 2024-12-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf6ff1e66b2882b8/dr-edward-kim-champions-diversity-and-innovation-in-cancer-clinical-trials-at-city-of-hope 2024-12-24T06:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/d4e9ce29d2062329/real-world-evidence-reveals-disparities-in-car-t-cell-therapy-outcomes-across-patient-demographics 2024-12-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c9507f27ba1aa3a3/2024-glp-1-breakthroughs-clinical-advances-and-regulatory-developments-transform-treatment-landscape 2024-12-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f3f884e9d6767e36/a-multi-center-open-label-randomized-clinical-trial-evaluating-the-preventive-effect-of-trials 2024-12-24T04:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/8cb305e178881cc6/new-migraine-drug-atogepant-shows-quick-relief-news-medical 2024-12-24T04:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/0d9420efa9a553a8/higher-sodium-intake-significantly-increases-atopic-dermatitis-risk-and-severity-uk-study-finds 2024-12-24T03:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/504432723462e5d8/polypid-announces-positive-recommendation-by-dsmb-to-continue-enrollment-of-phase-3 2024-12-24T01:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/1527aa8710711951/aplt-investor-alert-robbins-llp-reminds-stockholders-of-globenewswire 2024-12-24T00:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/550a7cd65703b526/anebulo-pharmaceuticals-advances-selonabant-development-with-fda-collaboration 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c1767f86b91ed34/vertex-pharmaceuticals-price-target-lowered-to-460-from-550-at-truist 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5412bdfde6e91416/who-tag-co-vac-reviews-covid-19-vaccine-effectiveness-and-antigen-composition 2024-12-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a6d9ba9338049c32/study-finds-transfusing-more-blood-reduces-risk-of-death-at-six-months-in-heart-attack 2024-12-23T22:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/a6083212b47c8507/anavex-life-sciences-corp-sec-10-k-report-tradingview 2024-12-23T22:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/1589ee745c87aa6c/most-read-stories-from-2024-drug-topics 2024-12-23T21:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/556900548a16e5b5/biomarker-selected-treatment-shows-promise-for-bladder-preservation-in-mibc 2024-12-23T21:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/0e9b5090f9c3bcff/prophylactic-tocilizumab-reduces-toxicity-boosts-efficacy-in-immune-checkpoint-inhibitor 2024-12-23T21:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/0f7aecbe33ece759/avita-medical-announces-fda-approval-of-recell-go-mini-globenewswire 2024-12-23T21:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/30b5347f1da303a6/published-aspire-data-show-noninferior-stone-free-rate-with-sure-vs-urs-urology-times 2024-12-23T20:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/eab6ddf7811fc177/irox-as-second-line-therapy-for-metastatic-colorectal-cancer 2024-12-23T19:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd498478edf37f17/top-10-breast-cancer-breakthroughs-in-2024-targeted-oncology 2024-12-23T18:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/dde942d727405ac1/we-ll-learn-about-ozempic-s-potential-for-alzheimer-s-disease-in-2025-new-scientist 2024-12-23T18:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/2ba2271bdf71f709/first-patient-dosed-in-marengo-s-invikafusp-alfa-trial-expansion-to-europe 2024-12-23T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc2d53961655b162/medicus-pharma-ceo-charts-course-for-2025-with-clinical-milestones-for-skinject 2024-12-23T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/ee162125638f9734/pfizer-advances-in-c-diff-vaccine-development-and-pneumococcal-shot-progress 2024-12-23T17:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/5eba45c4a1e4b545/signati-submits-de-novo-application-to-fda-after-completing-trial 2024-12-23T16:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/f990f28a11ba7c40/chemo-free-regimen-for-ph-all-yields-high-rate-of-deep-mrd-negativity 2024-12-23T16:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/68e6be9131849b1c/fda-approves-first-generic-of-once-daily-glp-1-injection-to-lower-blood-sugar-in-patients 2024-12-23T16:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/f3bcad66c42ac930/nvo-stock-plunges-as-obesity-drug-cagrisema-misses-target-in-phase-iii-barchart-com 2024-12-23T16:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/852d271ead5da42b/primary-analysis-of-zuma-2-treatment-of-btk-inhibitor-naive-relapsed-refractory-mantle 2024-12-23T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/7bce45cb0d6bd24b/avelumab-axitinib-vs-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2024-12-23T15:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/f65f8953f5fe55da/sequoia-5-year-follow-up-zanubrutinib-vs-bendamustine-rituximab-in-treatment-naive-cll-sll 2024-12-23T15:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/c6cb7ffffdb59fd8/rapt-therapeutics-and-shanghai-jemincare-pharmaceutical-globenewswire 2024-12-23T15:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/dbad5e6e3d1ef5cc/top-5-most-read-ipf-content-of-2024-american-journal-of-managed-care 2024-12-23T15:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/907b99d9e1f31260/long-term-overall-survival-with-adjuvant-gemcitabine-capecitabine-vs-the-asco-post 2024-12-23T15:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/6e1332a0990da0b3/deucravacitinib-outperforms-other-biologic-therapies-for-treatment-of-cutaneous-lupus 2024-12-23T15:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/8eb1f152fdeae4ac/bristol-myers-tyk2-inhibitor-shows-promise-in-phase-3-psoriatic-arthritis-trials 2024-12-23T15:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/83c312889a4b323f/keymed-biosciences-announces-approval-of-stapokibart-for-the-treatment-of-chronic 2024-12-23T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/68f5146893700e4e/sumitomo-pharma-america-announces-u-s-fda-approval-of-gemtesa-r-vibegron-for 2024-12-23T14:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/a21ef13fab0e505b/after-rejection-last-year-us-authorities-approve-new-hemophilia-drug-from-novo-nordisk 2024-12-23T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/news/c10f84231aa90c7f/xbiotech-pauses-rheumatology-program-the-manila-times 2024-12-23T14:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/fc468e9b2df613b7/u-s-food-and-drug-administration-accepts-for-priority-review-nuvation-bio-s-new-biospace 2024-12-23T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/d91bf0f5ac071025/axena-health-begins-patient-enrollment-for-ui-treatment-study-at-two-sites-in-nigeria 2024-12-23T14:22:36+00:00 weekly 0.7 https://trial.medpath.com/news/459568150a1a9c4e/evaluation-of-bacillus-coagulans-lmg-s-31876-on-immunomodulation-and-stress-frontiers 2024-12-23T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/eb183278d7c04807/most-significant-clincal-trials-of-2024 2024-12-23T14:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/7a5264dc0f4f57ea/puma-biotech-s-nerlynx-secures-major-nccn-guidelines-recognition-for-cervical 2024-12-23T14:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/fb187482fb11da3e/bristol-myers-sotyktu-phase-3-trials-in-psoriatic-arthritis-meet-primary-goals 2024-12-23T13:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/c3e9f04f4d924be5/wave-life-sciences-advances-novel-obesity-drug-wve-007-targeting-inhbe-gene 2024-12-23T13:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/cde76235b0842c49/vivos-inc-announces-launch-of-groundbreaking-radiogel-r-globenewswire 2024-12-23T13:38:44+00:00 weekly 0.7 https://trial.medpath.com/news/85e9f73f8de98e59/tailor-made-for-a-lifelong-pursuit-of-precision-in-cancer-care-onclive 2024-12-23T13:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/53d95249d2154c28/oak-bay-kid-turns-on-the-charm-for-clinical-trials-hub-at-bc-children-s-sooke-news-mirror 2024-12-23T13:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/48a81b7fc14cc0cb/signati-medical-successfully-completes-ide-trial-for-separo-vessel-sealing-system 2024-12-23T13:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/e17c9bf51e3f3c98/cosciens-biopharma-inc-provides-corporate-update-and-highlights-pipeline-prioritization 2024-12-23T12:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/d6dd9b592a1f4e1a/gain-therapeutics-advances-parkinson-s-treatment-phase-1b-trial-approved-after-stock-titan 2024-12-23T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/004208fbffd44a37/telomir-s-breakthrough-drug-shows-promise-for-wilson-s-disease-as-company-expands 2024-12-23T12:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/ccc0c46294b45399/glaukos-submits-new-drug-application-to-u-s-fda-for-epioxa-stock-titan 2024-12-23T12:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/40f6b4ab2ec0b031/traws-pharma-announces-progress-in-developing-tivoxavir-marboxil-for-h5n1-bird-flu 2024-12-23T12:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/ef3cb0013e18b4c3/eu-approves-opdivo-yervoy-combo-for-colorectal-cancer-investing-com 2024-12-23T12:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/56aec74a1f4352b0/protalix-biotherapeutics-issues-2025-letter-to-stockholders-stock-titan 2024-12-23T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/343f4420a93f02ec/study-unveils-nad-s-link-to-aging-and-disease-development-news-medical 2024-12-23T12:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/4c42984e4ae0ee53/novel-3d-osteosarcoma-spheroid-models-show-promise-for-enhanced-preclinical-drug-testing 2024-12-23T12:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/54b47a0cc1007704/study-reveals-significant-racial-and-mental-health-disparities-in-alopecia-areata-patients 2024-12-23T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/954fbaea633dd0f0/zura-bio-launches-groundbreaking-phase-2-trial-for-novel-dual-pathway-autoimmune-treatment 2024-12-23T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/e00dd58a0e115dad/nanoviricides-nv-387-shows-breakthrough-88-survival-rate-against-h5n1-bird-flu-in-key-study 2024-12-23T11:38:55+00:00 weekly 0.7 https://trial.medpath.com/news/02b079ae4c84a289/prediction-of-metabolic-subphenotypes-of-type-2-diabetes-via-continuous-glucose-monitoring 2024-12-23T10:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/5859808104fa1719/pig-kidney-transplants-new-schizophrenia-drug-here-are-5-of-the-biggest-medical-abc-news 2024-12-23T10:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/0012cada7e781c9d/nexalin-technology-advances-with-phase-1-completion-of-virtual-clinic-for-brain-stimulation-therapy 2024-12-23T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f27cccc501a5948c/effects-of-two-different-dexamethasone-dosing-regimens-on-ventilator-free-days-and-long 2024-12-23T09:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/c84505c048bbfc7f/preclinical-evaluation-of-bavdegalutamide-arv-110-a-novel-proteolysis-targeting 2024-12-23T09:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/fd58360aebb838a0/biophytis-showcased-the-oba-program-in-obesity-at-the-17th-scwd-international-congress 2024-12-23T09:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/eb99fea578f07948/molecular-testing-emerges-as-critical-factor-in-nsclc-treatment-decision-making 2024-12-23T09:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/278b48d48f956b6b/vivozon-pharmaceutical-to-launch-unafra-as-a-new-surgical-painkiller-market-in-h2-2025 2024-12-23T08:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/55b0761d4e959722/nationwide-recall-unapproved-epinephrine-nasal-solution-raises-safety-concerns 2024-12-23T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/54f06ed66ec21ecd/vittoria-biotherapeutics-doses-first-patient-in-phase-1-clinical-trial-of-viper-101 2024-12-23T07:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/9af4e2ca634373b9/usfda-gives-orphan-drug-designation-and-rare-paediatric-disease-biospectrum-asia 2024-12-23T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/f04a6d499464dd6e/tagrisso-approved-in-the-eu-for-patients-with-unresectable-egfr-mutated-lung-cancer 2024-12-23T07:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/d46267f1772771d5/exercise-shows-promise-in-managing-chemotherapy-induced-neuropathy-for-ovarian-cancer-patients 2024-12-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c498aaefec2205a0/press-release-sequana-medical-announces-us-fda-approval-of-globenewswire 2024-12-23T06:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/62f7be1ac1102501/ellipses-launches-pioneering-clinical-trial-programme-in-middle-east-morningstar 2024-12-23T06:16:55+00:00 weekly 0.7 https://trial.medpath.com/news/27414d085ab7f068/press-release-sanofi-initiates-phase-3-program-for-pcv21-globenewswire 2024-12-23T06:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/76769f21372f56b1/5-companies-that-celebrated-first-approvals-in-2024-biospace 2024-12-23T05:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/34a36a4e701db2a6/2024-highlights-the-rollercoaster-that-is-neuro-biospace 2024-12-23T05:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/7b679e5e14053271/study-reveals-cultural-and-spiritual-factors-impact-post-mastectomy-decisions-in-women-of-color 2024-12-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1505fab0fe30d90c/immunotherapy-in-nsclc-experts-address-patient-selection-and-access-challenges 2024-12-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5d00ca1926a0f16c/dextromethorphan-found-to-have-potential-in-treating-lung-fibrosis-news-medical 2024-12-23T04:35:50+00:00 weekly 0.7 https://trial.medpath.com/news/49fef87f2e6288d5/aua-2024-breakthrough-developments-in-male-contraception-bladder-cancer-treatment-and-health-equity-initiatives 2024-12-23T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2c5dc8078e8f45f/kinoxis-secures-2-5m-grant-for-dementia-agitation-treatment-clinical-trial-inside-ageing 2024-12-23T03:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/66240868ad13593b/top-oncology-healthcare-trends-of-2024-prior-authorization-pbm-reform-and-patient-navigation-lead-discussion 2024-12-23T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e1cf04ada9d7a60/application-of-indocyanine-green-human-serum-albumin-complex-in-fluorescence-image-trials 2024-12-23T02:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/75288e7dbea15928/celltrion-s-actemra-biosimilar-wins-approval-in-korea-bio-article-kbr 2024-12-23T02:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/579eb481bc5c6fec/gi-innovation-completes-1st-patient-dosing-of-subcutaneous-immunotherapy-potentially-for-melanoma 2024-12-23T01:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/79a44f8801154884/regarding-the-approval-of-the-additional-indication-for-endometriosis-in-europe-kituseiyao-pin-gong-ye 2024-12-23T01:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/9dbe327fe7c83053/daily-hong-kong-stock-market-news-briefing-december-23-monday-longport 2024-12-23T01:19:50+00:00 weekly 0.7 https://trial.medpath.com/news/87e4ec7f95a639d7/ai-clinical-trials-hit-record-numbers-in-2024-as-pharma-giants-embrace-technology 2024-12-23T01:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/2e044054264ad077/cstone-announces-submission-of-clinical-trial-application-in-australia-for-cs2009-pr-newswire 2024-12-23T00:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/9bc3589700d79131/oncolytics-biotech-inc-anticipates-key-clinical-data-readouts-in-2025 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/1898acd298c26cf5/sun-pharma-acquires-concert-pharmaceuticals-to-advance-alopecia-areata-treatment 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8dc594e87ba83d6/reviva-pharmaceuticals-reports-promising-preliminary-ole-data-for-brilaroxazine 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/da82d78824192afc/glp-1-receptor-agonists-show-lower-risk-for-mace-and-vte-in-lupus-and-type-2-diabetes-patients-compared-to-dpp4-inhibitors 2024-12-23T00:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/36f59e2fc06f8cf9/2024s-top-12-clinical-trials-cromos-pharma 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cb5cbdf180c3ec34/respiratory-syncytial-virus-rsv-vaccine-safety 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ace222460586e1a9/top-10-trigeminal-neuralgia-clinical-trials-2024-studies-power 2024-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e176a0b74a9ca361/prescient-therapeutics-gains-fda-approval-for-ptx-100-trial-tipranks-com 2024-12-22T23:51:50+00:00 weekly 0.7 https://trial.medpath.com/news/af2ed54f78176b8b/advancing-type-1-diabetes-therapy-autologous-islet-transplant-breakthrough-nature 2024-12-22T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/afae64e086aef65c/biowire-weekly-025-by-david-kingsley-phd-substack 2024-12-22T23:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/d74605cfe4f0cd5c/jhaveri-compares-safety-and-duration-of-adjuvant-cdk4-6-inhibitors-in-hr-breast-cancer 2024-12-22T20:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/779a2e39c7e305f8/curateq-biologics-receives-approval-for-oncology-biosimilar-bevqolva-from-uk-s-mhra 2024-12-22T18:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/f38b942289bc7dce/brexu-cel-yields-high-response-rates-in-relapsed-refractory-btk-naive-mcl 2024-12-22T18:39:37+00:00 weekly 0.7 https://trial.medpath.com/news/abd597c0c22d1afc/ongoing-research-seeks-to-optimize-targeted-therapy-use-in-mcrc-onclive 2024-12-22T17:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/36755704d77cb9e5/x-ray-brachytherapy-sustains-organ-preservation-in-early-rectal-cancer 2024-12-22T17:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/49cd58f036a90832/selective-antisense-oligonucleotide-based-jak2-inhibitor-receives-fda-orphan-drug 2024-12-22T16:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/d5c80cfc7af12341/gene-therapy-shows-long-term-vision-benefits-in-rare-eye-disease-medpage-today 2024-12-22T15:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/ebeb6cbd49ea42f4/vivani-medical-strategic-innovation-in-glp-1-obesity-treatment-justifies-buy-rating 2024-12-22T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/919967605f7af529/bioa-alert-the-investigation-on-behalf-of-bioage-labs-globenewswire 2024-12-22T12:46:27+00:00 weekly 0.7 https://trial.medpath.com/news/d4bd400fcdeac983/u-s-congress-drops-pbm-reform-from-year-end-funding-package-despite-bipartisan-support 2024-12-22T12:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/aeb2c8bfa88b9e34/comparison-of-brolucizumab-and-aflibercept-for-treating-dme-modern-retina 2024-12-22T11:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/9e7ba5c2d1fee46a/positive-clinical-trial-results-highlighted-in-recent-pharma-developments 2024-12-22T11:13:12+00:00 weekly 0.7 https://trial.medpath.com/news/32ff23dcc4ffa36c/prothena-s-parkinson-s-drug-fails-primary-endpoint-but-sparks-investor-interest 2024-12-22T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/94763b12d6ef6326/higher-ferritin-threshold-of-25mg-l-proves-cost-effective-for-iron-deficiency-screening-in-women 2024-12-22T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ce6aec5b6b53d41/study-reveals-tmb-levels-impact-immunotherapy-outcomes-in-breast-cancer-treatment 2024-12-22T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8c215b30ee40220/implementation-of-a-parent-training-intervention-sparck-to-prevent-childhood-mental-trials 2024-12-22T05:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/b4ef1007e8a2586a/research-shows-guillain-barre-syndrome-remains-rare-among-older-adults-after-rsv-vaccination 2024-12-22T04:36:02+00:00 weekly 0.7 https://trial.medpath.com/news/30d6feb70140b972/prior-car-t-cell-therapy-exposure-may-impact-odronextamab-benefit-in-dlbcl 2024-12-22T03:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/3910d043b92a8280/thousands-of-women-with-breast-cancer-may-soon-be-told-they-don-t-need-any-treatment 2024-12-22T02:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/dd6005e1bcc019bc/fda-approves-premarket-approval-application-for-oraquick-hiv-self-test-expanding 2024-12-22T02:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/8d38d59c814c1de2/hervolution-therapeutics-dark-genome-biotech-company-raises-11-7-million-series-a 2024-12-22T01:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/7766f4f75b3e7729/aim-weekly-movers-potential-resurrection-for-active-energy-uk-investor-magazine 2024-12-22T01:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/5075a775ddaa8bec/fda-approves-zepbound-for-sleep-apnea-yahoo 2024-12-22T00:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/93378f5af5f397f4/perioperative-pembrolizumab-regimen-upholds-survival-benefit-in-resectable-nsclc 2024-12-21T23:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/b5e844774748092d/could-mosquitoes-deliver-vaccines-against-malaria-health-news-al-jazeera 2024-12-21T20:26:27+00:00 weekly 0.7 https://trial.medpath.com/news/a5e561d58e4a7f0f/jefferies-sees-novo-dropping-at-least-10-15-on-obesity-data-yahoo-finance 2024-12-21T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/news/7b0ca3f955797c37/gholam-contrasts-lenvatinib-with-other-options-in-child-pugh-b-hcc-targeted-oncology 2024-12-21T18:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/41af0aad73d5b356/avacta-group-aim-avct-leading-the-way-in-precision-cancer-therapies-share-talk 2024-12-21T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/news/01d9407bbef5f9ac/achieving-a-2-67x-reduction-in-study-build-time-for-an-innovative-neuromodulation-study 2024-12-21T16:00:49+00:00 weekly 0.7 https://trial.medpath.com/news/47302117d9656223/a-new-perspective-on-drugs-for-duchenne-muscular-dystrophy-proposals-for-better 2024-12-21T15:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/65680e118569d85b/yoltech-therapeutics-announces-successful-completion-of-dose-escalation-phase-in 2024-12-21T14:45:03+00:00 weekly 0.7 https://trial.medpath.com/news/2df1024ceb732502/innovative-mrna-car-therapy-mt-303-under-study-for-liver-cancer-targeted-oncology 2024-12-21T13:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/faa4054c34caf2f6/pharmala-issues-audited-financial-statements-completes-globenewswire 2024-12-21T09:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/a0f50a2bc48eb8ee/rhythm-pharma-s-imcivree-wins-fda-approval-for-rare-obesity-treatment-in-young-children 2024-12-21T09:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/5eed0b4e3bfb3c38/polyrizon-inks-manufacturing-agreement-for-its-pl-14-allergy-blocker-with-eurofins-cdmo 2024-12-21T08:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/2bb3be5817835dc3/advances-in-transplant-eligibility-expand-treatment-options-for-secondary-aml-patients 2024-12-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f9d9441ee54d713/fda-grants-accelerated-approval-to-encorafenib-plus-cetuximab-and-chemo-for-braf-onclive 2024-12-21T06:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/f80c57573ff69a1e/fda-approves-alhemo-r-injection-as-once-daily-prophylactic-treatment-to-prevent-or-pr-newswire 2024-12-21T06:43:15+00:00 weekly 0.7 https://trial.medpath.com/news/edeb90e392a82df4/belapectin-misses-primary-endpoint-in-phase-3-mash-cirrhosis-portal-hypertension-trial 2024-12-21T05:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/29187dfe9d515dc1/healthcare-leaders-call-for-value-based-cancer-care-reform-to-address-cost-and-access-barriers 2024-12-21T05:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/78054f1b0e53675d/breaking-health-news-landmark-case-drug-developments-and-legal-battles 2024-12-21T05:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/b9386a9f0b9d5906/eli-lilly-s-obesity-drug-zepbound-approved-to-treat-sleep-apnea-in-u-s-stat-news 2024-12-21T05:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/613d91721aad8ad3/global-standardization-of-tils-assessment-marks-major-progress-in-breast-cancer-research 2024-12-21T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e11f64901f345ffd/critics-condemn-new-uk-puberty-blockers-clinical-trial-as-unethical-the-christian-institute 2024-12-21T03:42:27+00:00 weekly 0.7 https://trial.medpath.com/news/0f0f235dd1efcdcb/effect-of-iv-thrombolysis-with-alteplase-in-patients-with-vessel-occlusion-in-the-wake-up-trial 2024-12-21T02:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/9410b560f5b0cd3a/sorriso-pharma-s-uc-treatment-hits-phase-ib-endpoints-clinical-trials-arena 2024-12-21T02:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/cfe8c860438e75d5/factors-associated-with-male-recruitment-in-a-multi-site-randomized-behavioral-clinical-trial 2024-12-21T01:35:52+00:00 weekly 0.7 https://trial.medpath.com/news/d9500ed40158234d/top-5-nsclc-content-for-2024-american-journal-of-managed-care 2024-12-21T01:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/54622b0fdb122772/an-open-letter-to-dennis-j-selkoe-m-d-alzforum 2024-12-21T00:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/a23329dff50e6919/asymptomatic-brain-metastases-in-egfr-mutant-nsclc-medpage-today 2024-12-20T22:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/b0672c12992ffb04/lexicon-announces-receipt-of-complete-response-letter-for-zynquistatm-sotagliflozin 2024-12-20T21:35:25+00:00 weekly 0.7 https://trial.medpath.com/news/860db0c81eb256c3/vertex-announces-u-s-fda-approval-for-trikafta-elexacaftor-tezacaftor-ivacaftor-and 2024-12-20T20:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/2b2d366e5f3feff7/endevica-bio-advances-tcmcb07-to-phase-2-trial-for-preventing-chemotherapy-induced-weight-loss 2024-12-20T20:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/06cd35741863081d/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman-biospace 2024-12-20T20:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/2e4bc9ba584fc36f/blackstone-acquisition-of-clinical-trial-service-provider-not-opposed-subject-to-divestiture-of 2024-12-20T20:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/3b0fd25b6cf7521e/1-big-new-green-flag-for-crispr-therapeutics-stock-the-globe-and-mail 2024-12-20T19:26:40+00:00 weekly 0.7 https://trial.medpath.com/news/8717332156a3f0a4/fda-approves-humacyte-s-lab-grown-blood-vessels-in-milestone-for-regenerative-medicine 2024-12-20T19:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/6017716b7e164108/one-year-in-cancer-research-and-much-to-celebrate-nci 2024-12-20T18:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/336c7b72caf3e8f9/mindmed-launches-first-phase-iii-lsd-trial-a-new-psychedelic-mushroom-species 2024-12-20T18:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/9bda8a41411a888b/filling-unmet-needs-in-scac-is-key-as-incidence-rates-are-rising-onclive 2024-12-20T18:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/0b89729c2b37633e/primo-biotechnology-partners-with-antelope-surgical-solutions-for-first-fda-approved 2024-12-20T18:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/0866c5eb3c388712/the-kids-are-alright-miebo-and-xdemvy-at-year-1-healio 2024-12-20T17:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/e31960bd8a1f1ce7/gates-institute-s-top-stories-of-2024 2024-12-20T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/c5ad0d0782258960/using-data-patterns-to-proactively-improve-study-quality-applied-clinical-trials 2024-12-20T17:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/4ccf5e1a4c45defc/cms-proposes-medicare-coverage-for-transcatheter-tricuspid-replacement-medtech-dive 2024-12-20T17:36:02+00:00 weekly 0.7 https://trial.medpath.com/news/2b43cf3673d80d24/seastar-medical-s-device-to-treat-inflammation-in-esrd-receives-fda-breakthrough-designation 2024-12-20T17:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/caa28b555de5c526/jcr-pharmaceuticals-initiates-phase-iii-clinical-trial-of-jr-142-in-japan-a-long-yahoo-finance 2024-12-20T17:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/9f4ae31f85537c04/use-of-ibrutinib-in-early-stage-chronic-lymphocytic-leukemia-the-asco-post 2024-12-20T17:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/32681fd4beb72019/discussion-trial-to-prevent-multidrug-resistant-tb-in-kids-enca 2024-12-20T17:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/be4dc80867a96f34/updated-mcdonald-criteria-ushers-in-new-era-for-multiple-sclerosis-diagnosis 2024-12-20T17:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/7a98750c8ab33b77/breakthrough-study-revolutionizes-osteosarcoma-care-mirage-news 2024-12-20T16:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/2845e934231b11fc/curacle-presents-results-of-its-phase-2a-clinical-trial-of-cu06-for-dme 2024-12-20T15:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/8f156835fcca153a/phase-iii-mash-miss-sends-galectin-stock-tumbling-biospace 2024-12-20T15:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/e6ca5032c4ace698/researchers-investigate-potential-treatment-for-eliminating-hiv-from-the-brain 2024-12-20T15:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/53abb89ff79968e5/gene-therapy-trials-should-emphasize-transparency-not-secrecy-stat-news 2024-12-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/c3d1a9573a448989/zejula-jemperli-combo-shows-promising-responses-in-breast-cancer-subset-cure-today 2024-12-20T14:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/02a20a2b2b06e1ec/roivios-wins-fda-ide-for-renal-assist-device-massdevice 2024-12-20T14:22:15+00:00 weekly 0.7 https://trial.medpath.com/news/51a5c0b350b8c651/merit-medical-announces-fda-approval-of-the-wrapsody-cell-impermeable-endoprosthesis 2024-12-20T14:19:21+00:00 weekly 0.7 https://trial.medpath.com/news/3e0faec92be1c711/cansino-biologics-inc-announces-initiation-of-phase-ii-iii-clinical-trial-and-marketscreener 2024-12-20T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/06f604216792830c/cansino-biologics-inc-announces-initiation-of-phase-iii-clinical-trial-and-completion-of-first 2024-12-20T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/02970512defb5a50/aridis-pharmaceuticals-provides-corporate-update-on-clinical-developments-and-financial-strategy 2024-12-20T14:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9c379e048711973/treatment-strategies-evolve-for-hr-her2-metastatic-breast-cancer-experts-weigh-in-on-site-specific-approaches 2024-12-20T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/135b039502ce0948/aethlon-medical-provides-update-on-the-ability-of-its-hemopurifier-r-to-capture-h5n1-bird-flu 2024-12-20T14:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/2a184130ea27ef43/braincool-ab-publ-adds-two-centers-to-the-cottis-2-clinical-study-of-its-cooling-systems-in 2024-12-20T13:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/f453d4ca6c979f4c/apollomics-phase-3-trial-in-china-shows-no-benefit-investing-com 2024-12-20T13:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/79d08d2df4353d53/rad-202-receives-approval-to-start-phase-1-therapeutic-trial-stock-titan 2024-12-20T13:13:49+00:00 weekly 0.7 https://trial.medpath.com/news/08abb8142a6a6630/kidney-cancer-research-program-drives-breakthrough-discoveries-with-50m-funding-boost 2024-12-20T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0f764e4f83c93fb/novo-nosedives-on-underwhelming-cagrisema-phase-iii-weight-loss-data-biospace 2024-12-20T12:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/72e8984b1caf8ac9/translating-molecular-analysis-of-brain-tumors-into-patient-treatment-mayo-clinic 2024-12-20T12:46:44+00:00 weekly 0.7 https://trial.medpath.com/news/409620935a4fc1a2/humacyte-shares-surge-38-on-fda-approval-of-symvess-morningstar 2024-12-20T12:28:04+00:00 weekly 0.7 https://trial.medpath.com/news/bc6f2017a95975d8/innovent-receives-approval-of-dovbleron-r-taletrectinib-adipate-capsule-ros1 2024-12-20T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/132da65575050417/marengo-announces-first-patient-dosed-in-phase-2-clinical-study-for-its-lead-pr-newswire 2024-12-20T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/f35a2ff4be8e75ca/regeneron-advances-anticoagulant-antibody-pair-to-late-stage-testing-firstword-pharma 2024-12-20T12:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/f3a04d17d59a7717/cytokinetics-announces-sanofi-acquired-rights-to-develop-and-commercialize-aficamten-in 2024-12-20T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/b64fb57f80bd3936/summit-therapeutics-future-prospects-and-investment-considerations 2024-12-20T11:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/b91f53e5831f367a/stem-cells-head-to-the-clinic-treatments-for-cancer-diabetes-and-parkinson-s-disease-could 2024-12-20T11:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/fb3ba9494987d837/fennec-s-pedmarqsi-r-breakthrough-first-nhs-treatment-for-child-cancer-related-hearing-loss 2024-12-20T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/fbaa0743ca351755/antibiotics-do-not-increase-risks-for-cognitive-decline-dementia-in-older-adults-new-data-says 2024-12-20T11:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/1ae8feb08214a30f/summary-report-on-authorisation-lytgobi-r-swissmedic 2024-12-20T10:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/c3c0d94fd5444ecb/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate-against-biospace 2024-12-20T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/1239263dc23f8f55/hot-stocks-exosome-breakthrough-gas-pipeline-deals-and-more-sharecafe 2024-12-20T10:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/8ffd118d946e2374/gsk-reports-mixed-findings-from-ovarian-cancer-phase-iii-study-shares-magazine 2024-12-20T09:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/31f78067a487df10/synairgen-backer-ready-to-pump-ps18-ps19-million-into-phase-ii-trial-aim-sng-otc-syggf 2024-12-20T08:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/f7757e6dd7ac360d/a-venture-firm-breathes-new-life-into-an-old-ngm-drug-biopharma-dive 2024-12-20T08:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/339095ab42fb4fac/oncodesign-precision-medicine-reacquires-rights-to-its-opm-201-program-from-servier 2024-12-20T07:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/574eb9ff4c7b959b/a-phase-2-pilot-study-of-umbilical-cord-blood-infusion-as-an-adjuvant-consolidation-therapy 2024-12-20T07:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/53e911361ece6897/novel-mri-biomarker-shows-promise-for-early-detection-of-heart-damage-in-duchenne-muscular-dystrophy 2024-12-20T07:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4a2dc6bbba0198b/evaluating-sirna-therapy-fitusiran-in-combination-with-antithrombin-modulation-for-hemophilia 2024-12-20T07:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/17fbab35bc232448/crism-therapeutics-partners-with-aixial-group-for-phase-2-glioblastoma-trial-tipranks 2024-12-20T07:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/d0bd04bfc6bb1d20/breakthrough-treatments-transform-landscape-for-rare-hemolytic-anemias-from-c5-inhibitors-to-novel-therapeutic-approaches 2024-12-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d291d2b6b2b2653/inflarx-announces-first-patient-dosed-in-phase-2a-study-for-csu-and-hs 2024-12-20T06:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5a52162c3c36f88/car-t-therapy-shows-promise-in-earlier-treatment-lines-for-relapsed-refractory-multiple-myeloma 2024-12-20T06:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/d64b9f78e37d78de/experts-highlight-advances-in-lung-cancer-treatment-immunotherapy-adcs-and-equity-in-care 2024-12-20T05:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/a864387e2d3c6d6f/onward-medical-receives-fda-de-novo-classification-and-us-globenewswire 2024-12-20T04:59:59+00:00 weekly 0.7 https://trial.medpath.com/news/130bb4025b592179/moderna-begins-phase-3-cove-study-for-covid-19-mrna-vaccine 2024-12-20T04:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/604ad8b972d71a57/engene-reports-full-year-2024-financial-results-and-provides-a-business-update 2024-12-20T04:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/f4ed05fa04e5188d/limited-treatment-options-highlight-critical-role-of-rsv-prevention-in-high-risk-adults 2024-12-20T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2abac64ae6949331/stemcyte-announces-successful-phase-iia-clinical-trial-results-for-hpc-cord-blood-in 2024-12-20T03:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/c30e451a1eb25f20/humacyte-announces-fda-approval-of-symvesstm-acellular-globenewswire 2024-12-20T03:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/54928f0fa80df18f/vunakizumab-shows-promise-in-treating-active-ankylosing-spondylitis-in-phase-2-3-study 2024-12-20T03:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4ddb9321425948d/study-highlights-interim-results-on-abrocitinib-for-adolescents-adults-with-atopic-dermatitis 2024-12-20T03:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/d0a6dc7d763cb46a/immix-biopharma-announces-positive-u-s-clinical-data-from-globenewswire 2024-12-20T02:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/69a83ed7b0897ffc/vanderbilt-researchers-achieve-milestone-in-alzheimer-s-drug-development-news-medical 2024-12-20T01:45:09+00:00 weekly 0.7 https://trial.medpath.com/news/8041901d383acd2d/irregular-assessment-times-in-pragmatic-randomized-clinical-trials-biomed-central 2024-12-20T01:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/1eaa2d838b79ef38/igc-pharma-to-participate-in-biopartnering-at-jpm-alongside-j-p-morgan-healthcare-conference-2025 2024-12-20T00:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5fec2574f32eaac/global-trial-of-mrna-vaccine-for-norovirus-underway-amid-surge-in-cases 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e93726800c4ced0/comprehensive-review-of-lupus-nephritis-randomized-controlled-trials-highlights-evidence-gaps-and-under-represented-populations 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/61a28d31202a9af7/novos-cagrisema-disappoints-in-pivotal-trial 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa5e63bc2b582127/gozetotide-shows-promise-in-psma-positive-prostate-cancer-diagnosis-and-treatment 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/557e8efe13ff9986/pfizer-issues-2025-financial-outlook-and-other-pharma-updates 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8b4bc4d774c1c6df/akamis-bio-secures-60-million-for-cancer-gene-therapy-development-and-partners-with-xuanzhu-biopharma 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/76040f798a8f08e5/sotagliflozin-may-lower-hba1c-without-raising-risks-for-adults-with-type-1-diabetes-ckd 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a0beeec999785399/b-riley-upgrades-cognition-therapeutics-to-buy-following-positive-lewy-bodies-data 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/47220a385a8a9169/cell-therapy-shows-promise-for-ebv-driven-post-transplant-lymphoproliferative-disease 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eee12189a2f643d8/ucsf-conducts-clinical-trials-to-improve-prostate-cancer-treatment 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddf65d99165e3ab6/rhythm-pharmaceuticals-targets-rare-obesity-disorders-with-promising-treatments 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56075e59728e7337/the-year-in-drugs-boulder-weekly 2024-12-19T23:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/34ddcfaa7b58508d/abortion-law-changes-could-threaten-women-s-participation-in-us-clinical-trials 2024-12-19T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/64274111f92f5c88/preventive-levofloxacin-found-to-reduce-drug-resistant-tb-in-household-contacts-cidrap 2024-12-19T22:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/e8f519827efb4f99/sarepta-completes-subject-dosing-in-phase-iii-lgmd2e-r4-therapy-trial 2024-12-19T22:34:18+00:00 weekly 0.7 https://trial.medpath.com/news/f02951642f954527/ionis-wins-fda-approval-for-a-rare-disease-therapy-that-lowers-triglycerides-stat-news 2024-12-19T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/607a4c4db00caeb5/exelixis-downgraded-to-market-perform-despite-price-target-increase-to-40 2024-12-19T22:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b1d122c2adb01f7/pepromene-bio-secures-11-million-investment-to-advance-baff-r-car-t-cell-therapy-for-follicular-lymphoma 2024-12-19T21:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/3462b8945dda68e9/drug-farm-partners-with-nih-to-develop-treatment-for-rosah-syndrome 2024-12-19T21:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/6da10400b1a09413/italy-joins-the-list-of-countries-recommending-restrictions-on-puberty-blockers-for-gender 2024-12-19T21:41:15+00:00 weekly 0.7 https://trial.medpath.com/news/67a4eed823017959/myriad-genetics-riskscore-study-named-one-of-the-top-10 2024-12-19T21:17:09+00:00 weekly 0.7 https://trial.medpath.com/news/894e74308cd2ffaf/ultragenyx-announces-first-patient-dosed-in-pivotal-phase-3-globenewswire 2024-12-19T21:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/53e9337c966c9e4d/odronextamab-demonstrates-safety-in-treating-dlbcl-population-cancer-network 2024-12-19T21:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/e4a21135bdbb49a9/parents-can-reliably-report-their-child-s-eoe-symptoms-over-time-research-horizons 2024-12-19T20:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/6971c80f8dcdee70/newest-chikungunya-vaccine-candidate-s-benefits-are-measurable-vax-before-travel 2024-12-19T20:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/86494fdb80b4b366/patients-with-disability-facing-barriers-to-access-clinical-trials-for-new-drugs-and-treatments 2024-12-19T20:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/4c48354f05ae3780/federal-jury-awards-lindis-biotech-50-million-in-patent-infringement-case-against-amgen-s-blincyto 2024-12-19T20:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/d21559bc67b97491/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2024-12-19T19:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/c1aecffb1d92049f/lexaria-s-registered-glp-1-study-4-begins-dosing-stock-titan 2024-12-19T19:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/203b567eed26a7cb/nab-paclitaxel-combo-improves-response-vs-soc-in-her2-breast-cancer 2024-12-19T19:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/4c1329ea29c5b62f/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2 2024-12-19T18:51:37+00:00 weekly 0.7 https://trial.medpath.com/news/34bfcb04b21656fa/apac-leading-in-parkinson-s-disease-clinical-trials-yahoo-finance 2024-12-19T18:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/1f10f13c3f4521b3/phase-iii-swift-trials-show-ultra-long-acting-biologic-depemokimab-reduces-severe 2024-12-19T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/9645df3743ca5a67/targed-doses-first-participant-in-phase-1-clinical-trial-of-groundbreaking-thrombolytic 2024-12-19T17:27:49+00:00 weekly 0.7 https://trial.medpath.com/news/a89146912213cfb4/review-clinical-trials-demonstrate-effectiveness-of-cannabinoids-for-managing-peripheral 2024-12-19T17:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/a0430015461fccdc/uc-davis-health-premieres-new-documentary-on-duchenne-muscular-dystrophy-treatment 2024-12-19T17:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/56d0c8bd62ac9413/wayne-state-university-enrolls-first-michigan-patient-in-clinical-trial-of-procedure-that-may 2024-12-19T16:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/e16dff8e470df786/rationale-and-design-of-a-large-trial-of-perioperative-ketamine-for-prevention-of-chronic-post 2024-12-19T16:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/7bf78d5295c7bfbf/astria-therapeutics-expands-stock-incentive-plan-to-attract-top-talent 2024-12-19T16:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f1a0ab5f7364add/2024-expert-insights-more-options-than-ever-dermatology-times 2024-12-19T16:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/2c663c82d906cc39/tiximed-announces-a-2-65m-program-related-investment-from-the-helmsley-charitable 2024-12-19T16:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/fc5619675a3aafda/decades-of-work-leads-to-clinical-trial-for-early-alzheimer-s-treatment-newsroom 2024-12-19T16:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/37347f94b4b9ca21/vertex-pharmaceuticals-inc-under-investigation-for-securities-fraud 2024-12-19T15:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c387065f161f129/emerging-treatments-for-chronic-hand-eczema-show-promise-in-closing-treatment-gap 2024-12-19T15:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/2e1694bdfdb3b1ea/alpelisib-plus-fulvestrant-in-pik3ca-mutated-hormone-receptor-positive-her2-negative 2024-12-19T15:27:06+00:00 weekly 0.7 https://trial.medpath.com/news/d9d5e46839bf4026/immunocore-doses-first-subject-in-gastrointestinal-cancer-therapy-trial 2024-12-19T15:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/3c4db719ac3497e8/hope-biosciences-research-foundation-authorized-to-begin-phase-ii-clinical-trial-in-stem 2024-12-19T15:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/52d1b53cbf6a59c9/fda-greenlights-phase-1-2-trial-of-gene-editing-therapy-for-primary-hyperoxaluria-1 2024-12-19T14:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/c2a9bc1c03843a65/biogencell-receives-fda-fast-track-designation-with-expanded-access-for-bgc101 2024-12-19T14:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/b9b5ed3ebbd56c43/opus-genetics-receives-fda-agreement-under-special-protocol-assessment-for-phase-3 2024-12-19T14:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/4555dac6cb085d7b/omeros-narsoplimab-shows-breakthrough-3-fold-mortality-reduction-in-pivotal-ta-tma-trial 2024-12-19T14:33:04+00:00 weekly 0.7 https://trial.medpath.com/news/42ba55cbdc691c97/could-the-tb-vaccine-in-phase-3-trials-in-malawi-be-a-game-changer 2024-12-19T14:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/69b5c068a5adc350/envoy-medical-names-seven-investigational-sites-for-participation-in-its-pivotal-clinical-study 2024-12-19T14:19:15+00:00 weekly 0.7 https://trial.medpath.com/news/1ff3652750d437bf/ultragenyx-submits-biologics-license-application-to-the-u-s-fda-for-ux111-aav-gene-biospace 2024-12-19T14:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/f399c8ed55464d74/study-validates-long-term-efficacy-of-micropulse-tlt-for-glaucoma-management 2024-12-19T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/3ac92e7d4284bfed/pluri-congratulates-mesoblast-on-fda-approval-of-first-globenewswire 2024-12-19T13:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/1bfef5b62c28060d/ptc-therapeutics-seeks-fda-approval-for-groundbreaking-friedreich-ataxia-treatment-in-children 2024-12-19T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/6759fdd034dc06d9/nls-pharmaceutics-and-kadimastem-announce-the-submission-of-a-request-by-morningstar 2024-12-19T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/c943f0631ee3d023/mainz-biomed-forms-agreement-with-quest-diagnostics-to-provide-clinical-trials 2024-12-19T13:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/2f82903fc5c2b776/alumis-announces-positive-phase-1-data-for-cns-penetrant-tyk2-inhibitor-a-005 2024-12-19T13:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/28b64d68ceb9223e/scottish-patient-pioneers-new-cancer-treatment-in-europe 2024-12-19T12:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/9e3e905593fdd5c7/prothena-s-parkinson-s-study-fails-primary-endpoint-despite-some-success 2024-12-19T12:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/b2cde2d521efbc6a/mindmed-to-be-added-to-the-nasdaq-biotechnology-index-company-announcement-markets-data 2024-12-19T12:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/1dc887847a545db9/mesoblast-shares-soar-on-fda-approval-for-ryoncil-therapy-capital-brief 2024-12-19T12:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/64fbdcb60e21ba49/regeneron-s-novel-blood-clot-prevention-drugs-show-breakthrough-results-in-phase-2-trial 2024-12-19T12:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/6bc52c5019343b70/vertex-sinks-with-placebo-showing-similar-results-to-pain-drug-bnn-bloomberg 2024-12-19T12:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/516ff54dbd44e69e/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational 2024-12-19T11:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/baad10c6b27464c4/remedy-plan-commences-dosing-in-phase-i-cancer-therapy-trial-clinical-trials-arena 2024-12-19T11:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/cc65195951b5a698/rheacell-receives-ema-approval-for-allo-apz2-cvu-phase-3-trial-in-chronic-venous-ulcers 2024-12-19T10:59:59+00:00 weekly 0.7 https://trial.medpath.com/news/56a9010c24677118/iarc-project-among-nature-medicine-list-of-clinical-trials-to-shape-medicine-in-2025 2024-12-19T10:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/038c9f26607469c8/omeros-corporation-s-narsoplimab-meets-primary-endpoint-in-pivotal-trial-for-stem-cell-transplant-patients 2024-12-19T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/c060087b09bc8e3b/coherus-to-present-final-phase-2-data-on-casdozokitug-in-liver-cancer-next-month 2024-12-19T10:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/4748ebd4635a74bd/canadian-survey-reveals-care-disparities-in-mds-aml-treatment-for-elderly-patients 2024-12-19T09:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/68eb40caf1e926a0/results-from-the-first-cardiac-lead-post-approval-study-using-real-wor-por 2024-12-19T08:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/8198ed877203e892/precision-neuroscience-secures-102m-series-c-for-non-invasive-brain-computer-interface-development 2024-12-19T07:48:58+00:00 weekly 0.7 https://trial.medpath.com/news/578d34fd0b6f6368/bioxodes-meets-enrollment-milestone-in-phase-2a-intracerebral-hemorrhagic-stroke-trial 2024-12-19T07:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/6172940f2e026cbe/rna-therapy-market-set-to-reach-4-16-billion-by-2034-as-clinical-trials-accelerate 2024-12-19T07:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/b63421617722ec0d/6-revolutionary-tech-developments-that-defined-2024 2024-12-19T06:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d9bb828b85dd752/ildong-pharmaceutical-announced-on-the-19th-that-it-will-seek-to-re-apply-after-strengthening-clinic 2024-12-19T06:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/955ac08c6d00b8c0/oruka-therapeutics-initiates-dosing-in-phase-1-trial-for-orka-001 2024-12-19T06:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/6433c22e3599e633/holoclara-initiates-phase-1-clinical-trial-evaluating-worm-derived-therapeutic-hc002-in 2024-12-19T06:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/97c0535366cf5d2d/standard-belzutifan-dose-equally-effective-as-higher-dose-in-ccrcc-targeted-oncology 2024-12-19T06:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/0eeb4a2a541e7c6f/cognition-therapeutics-price-target-increased-by-h-c-wainwright 2024-12-19T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/e6144c9130248fe2/marker-therapeutics-reports-positive-clinical-outcomes-for-mt-601-in-lymphoma-patients 2024-12-19T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/94df56bd9f7f67d5/novartis-to-close-morphosys-sites-cut-330-jobs-amid-pelabresib-development-challenges 2024-12-19T04:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/fdaa3849a87adb17/biopharma-job-market-shows-signs-of-recovery-despite-continued-layoffs-in-2024 2024-12-19T04:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/1892ff9dc62a6354/ira-impact-cdmos-adapt-to-navigate-small-molecule-drug-development-challenges 2024-12-19T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee6fa1c62aa4b79b/pharma-mar-sa-achieves-recruitment-milestone-in-phase-iii-cancer-trial 2024-12-19T02:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/fcdbb7af7b8f2f59/open-philanthropy-backs-the-search-for-new-cures-through-old-treatments 2024-12-19T00:48:52+00:00 weekly 0.7 https://trial.medpath.com/news/cb5f5561cb058c18/starpharma-receives-positive-feedback-from-fda-on-dep-r-sn38-clinical-pathway-for 2024-12-19T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/9709b474b26fd201/tnf-pharmaceuticals-announces-trial-to-explore-effects-of-lead-candidate-in-sarcopenia-frailty-induced-by-glp-1-weight-loss-drugs 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f710e34295a95d7b/sapience-therapeutics-receives-fda-orphan-drug 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/92898bb6de203918/real-world-data-shows-rsv-vaccine-s-effectiveness-in-older-adults 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a2e0eff94c189a07/advancements-in-pd-l1-immunohistochemistry-and-digital-pathology 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5bb73be3ad91a976/polyrizon-strengthens-leadership-with-appointment-of-dr-michal-meir-as-senior-director-of-regulatory-and-clinical-affairs 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75309855cfb846d9/valneva-expands-chikungunya-vaccine-access-in-asia-through-collaboration-with-serum-institute-of-india 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/231457e9bd972043/cell-source-unveils-breakthrough-in-off-the-shelf-car-t-cell-therapy-at-ash-meeting 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3abcc7f523c636e/all-11-sectors-sell-off-but-mesoblast-jumps-52pc-on-fda-nod 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/19e2976d7b20bfba/assembly-biosciences-secures-30-1-million-investment-from-gilead-to-boost-clinical-development 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5981170b8889c07b/percheron-therapeutics-ends-clinical-trial-in-australia-and-europe 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eec03a79821b4c6a/biomea-fusion-faces-challenges-with-clinical-hold-on-diabetes-drug 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66628eb92b9a5609/cannabidiol-linked-to-better-social-executive-function-in-tuberous-sclerosis-complex 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6572ff2a7c005d1f/heartbeam-announces-us-fda-clearance-for-at-home-high-fidelity-heart-monitoring-technology 2024-12-18T23:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/01ac9cab065a9d5a/phase-ii-trial-of-risk-enabled-therapy-after-neoadjuvant-chemotherapy-for-muscle 2024-12-18T22:37:04+00:00 weekly 0.7 https://trial.medpath.com/news/47be89f690acd391/ascletis-announces-asc47-a-muscle-preserving-weight-loss-drug-candidate-for-pr-newswire 2024-12-18T22:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/14178eeb68927afc/new-molecular-imaging-agent-can-accurately-identify-crucial-cancer-biomarker 2024-12-18T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/feeba69285072f18/io-trials-change-practice-in-localized-and-metastatic-bladder-cancer-targeted-oncology 2024-12-18T22:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/da5af59922d6d582/sabcs-2024-breast-cancer-trial-updates-and-highlights 2024-12-18T21:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/6dee53105c339293/health-data-works-receives-fda-breakthrough-device-designation-for-access-trackertm 2024-12-18T21:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/3b9862cfed6fed7a/savara-s-molbreevi-advances-toward-first-ever-apap-treatment-with-fda-rolling-bla 2024-12-18T21:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/9253a440d8fd32ce/fda-greenlights-expansion-of-bivacor-artificial-heart-study-massdevice 2024-12-18T21:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/7c7b85268d83db2e/recent-sec-case-against-biotech-company-highlights-the-intersection-between-fda 2024-12-18T20:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/fb8bbc4b7a6083a0/c4-therapeutics-stock-hits-52-week-low-amid-market-volatility 2024-12-18T20:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/3115b8e694ea6db9/framework-amending-the-uk-clinical-trial-regulations-laid-before-parliament-jd-supra 2024-12-18T19:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/672051607f4be316/top-10-findings-shaping-the-future-of-breast-cancer-care-from-sabcs-2024 2024-12-18T19:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/294627e500caa931/consolidation-durvalumab-improves-pfs-in-unresectable-stage-iii-nsclc-without 2024-12-18T19:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/0f08b245ac60e628/cymbalta-bottles-recalled-1-in-3-older-adults-are-lonely-walking-off-depression 2024-12-18T18:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/38eb3507f9376738/verastem-oncology-provides-a-clinical-update-for-ramp-203-trial-in-advanced-kras-biospace 2024-12-18T18:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/391958139b257102/tiziana-life-sciences-announces-first-patient-with-moderate-alzheimer-s-disease-dosed 2024-12-18T18:23:12+00:00 weekly 0.7 https://trial.medpath.com/news/45d71a454a8de903/vandria-announces-first-subjects-dosed-in-its-first-in-human-phase-1-clinical-trial-of-vna-318 2024-12-18T18:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/314109cf7529d1bd/clinical-trial-to-evaluate-minimally-invasive-procedure-for-women-with-pelvic-venous-disease 2024-12-18T17:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/70792426827df6da/breckenridge-announces-final-fda-approval-for-methadone-hydrochloride-multi-dose-injection 2024-12-18T17:33:46+00:00 weekly 0.7 https://trial.medpath.com/news/fa055a9aa7e69af3/karmanos-cancer-institute-physicians-begin-prescribing-new-fda-approved-pr-newswire 2024-12-18T17:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/0b84b8fbbd870472/ose-immunotherapeutics-to-present-anti-il-7r-lusvertikimab-globenewswire 2024-12-18T17:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/a799062336a425fd/mount-sinai-study-reveals-immune-modulatory-mechanism-of-lurbinectedin-in-small-cell 2024-12-18T16:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/934f5f060b92b56c/perceived-barriers-and-facilitators-of-staff-recruiting-participants-to-a-randomised-controlled-trials 2024-12-18T16:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/2b2c2c3c7c152e32/limitation-of-site-stratified-cox-regression-analysis-in-survival-data-trials-biomed-central 2024-12-18T16:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/2ca1cfb7b9d6ae44/primary-lung-tumor-sbrt-followed-by-concurrent-mediastinal-chemoradiotherapy-and 2024-12-18T16:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/df75e98b482c31d0/car-t-cell-therapy-emerges-as-promising-treatment-for-systemic-lupus-erythematosus 2024-12-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efafccf7039acb03/uk-veterinary-authorities-confirm-histamine-contamination-in-equine-antibiotic-batches-following-adverse-event-investigation 2024-12-18T15:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/ba7ec85948b20f46/omacetaxine-plus-azacitidine-for-excess-blasts-mds-safety-long-term-outcomes-favorable 2024-12-18T15:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/63e261d14a48349a/east-texas-doctor-gets-fda-approval-for-new-back-pain-procedure-cbs19-tv 2024-12-18T15:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/1c4237ecf909ac55/arthrosi-therapeutics-surpasses-50-patient-enrollment-in-pivotal-phase-3-reduce-2 2024-12-18T14:33:22+00:00 weekly 0.7 https://trial.medpath.com/news/d9ddb9611bc7238c/metavia-announces-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241 2024-12-18T14:28:20+00:00 weekly 0.7 https://trial.medpath.com/news/70fccc58de618c97/innovative-car-e-therapy-extends-cancer-free-period-for-patients 2024-12-18T14:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/6aeafee484b30468/tenya-therapeutics-sees-mixed-success-in-hcm-gene-therapy-trial-clinical-trials-arena 2024-12-18T14:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/83865d4431ba7ef1/coya-therapeutics-provides-enrollment-update-of-the-investigator-initiated-phase-1-study-of 2024-12-18T14:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/121d6a56d365727a/advances-in-breast-cancer-surgery-offer-patients-improved-surgical-outcomes 2024-12-18T14:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/eccc6042f716b6c8/monogram-technologies-provides-510-k-submission-update-following-positive-meeting-with-fda 2024-12-18T13:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/49c8db9356d9abfe/contemporary-pediatrics-top-3-fda-approvals-of-2024 2024-12-18T13:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/9314865fc5ced0b6/fda-veozah-first-hormone-free-hot-flash-drug-issued-black-box-warning 2024-12-18T13:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/3e58d8d3ceeadb03/praxis-precision-medicines-announces-rare-pediatric-disease-globenewswire 2024-12-18T13:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/8bf5bb2799e67a46/acalabrutinib-regimen-demonstrates-efficacy-in-de-novo-mantle-cell-lymphoma-onclive 2024-12-18T13:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/dd78df814ab172b1/zyversa-to-showcase-breakthrough-kidney-disease-drug-at-jpm-healthcare-conference-2025 2024-12-18T12:57:05+00:00 weekly 0.7 https://trial.medpath.com/news/9d2c0b5e21f9430d/evaluation-of-gecacitinib-vs-hydroxyurea-in-patients-with-intermediate-2-or-high-risk-myelofibrosis 2024-12-18T12:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/1588f2e0910e4903/neurizon-files-ind-application-to-support-healey-als-platform-trial-yahoo-finance 2024-12-18T12:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/5017ad41619ad959/genentech-seeks-accelerated-fda-approval-for-brain-tumor-treatment 2024-12-18T12:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/973ea9d56c0daa85/controversial-covid-study-that-promoted-unproven-treatment-retracted-after-four-year-saga 2024-12-18T12:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/8555f9980b16f00d/first-in-vivo-gene-editing-trial-for-hepatitis-b-approved-in-hong-kong-dtil-stock-news 2024-12-18T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/8b7dbc57bb18e880/aurion-biotech-announces-topline-results-from-phase-1-2-trial-of-aurn001-for-corneal-edema 2024-12-18T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/6f7c5c4692e1ce51/viatris-announces-publication-of-phase-2b-care-study-data-for-cenerimod-in-lancet-rheumatology 2024-12-18T12:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/0f7599afeaea557b/positive-results-advance-peanut-tablet-to-phase-ii-development-globenewswire 2024-12-18T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/86c9c2493b49b8f9/fred-hutchinson-biostatistician-pioneers-novel-approaches-in-cancer-clinical-trial-design 2024-12-18T12:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/ea5dfb630c4f4cd4/gan-lee-s-novel-glp-1-drug-gets-fda-green-light-for-head-to-head-trial-against-eli 2024-12-18T11:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/178313f5f4b519bd/biopharma-s-manufacturing-push-and-other-2024-trends-biospace-iheart 2024-12-18T11:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/92b383be48dce9ea/further-research-on-balloon-guide-catheters-required-following-inconclusive-protect-mt-results 2024-12-18T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/e35c1816ef4cbe3d/johnson-johnson-submits-application-to-the-european-medicines-agency-seeking-biospace 2024-12-18T10:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/b3a921dc828ce003/patient-navigation-services-evolve-in-oncology-care-new-cms-codes-and-implementation-challenges-discussed-at-pcoc-2024 2024-12-18T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15647798ca2dd53e/egyptian-drug-authority-approves-lilly-and-eva-s-insulin-injection-yahoo-finance 2024-12-18T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/3907d9f7fcc27628/nccn-reports-progress-in-cancer-care-access-despite-ongoing-drug-shortage-challenges 2024-12-18T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/38317684a600138e/financial-toxicity-remains-major-barrier-in-cancer-care-despite-improved-patient-experience 2024-12-18T08:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ec2b06d9f2b8a86/oncology-clinical-pathways-need-rapid-updates-to-keep-pace-with-treatment-innovation 2024-12-18T08:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/e22d69abf3f5da95/applied-dna-customer-uhkt-initiates-phase-i-clinical-trial-of-uhkt-car123-01 2024-12-18T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/2e12089cc3e6b50a/oncology-pharmacists-expand-clinical-roles-push-for-provider-status-recognition 2024-12-18T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/61adb5ff3967db3d/breakthrough-antimicrobial-technology-with-unrivalled-efficacy-poised-to-revolutionise-global 2024-12-18T08:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/5bcb2f07c7c85a22/vancouver-biotech-briacell-to-raise-us-5-5-million-in-share-offering 2024-12-18T08:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/af6813614cae6b1a/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-for-invasive-fungal-infections 2024-12-18T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad5d2595636e5b1e/jenavalve-announces-first-case-in-new-heart-valve-registry-massdevice 2024-12-18T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4d7bd427f8c4114/thermo-fisher-scientific-and-eversana-partner-to-advance-ngs-based-precision-medicine-in-blood-cancers 2024-12-18T07:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/fcaf19a7b7d3d282/scipher-medicine-expands-precision-medicine-partnerships-to-transform-rheumatoid-arthritis-treatment 2024-12-18T06:37:44+00:00 weekly 0.7 https://trial.medpath.com/news/a59c0b84130e1a07/eli-lilly-s-alzheimer-s-treatment-kisunla-secures-fourth-major-market-approval-with-nmpa 2024-12-18T05:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/30c987887a6319f7/sanofi-teva-say-study-results-show-gut-disease-drug-could-be-best-in-class 2024-12-18T05:28:35+00:00 weekly 0.7 https://trial.medpath.com/news/f11a950bb5bf7c05/actuate-sees-37-cut-in-risk-of-death-in-phase-ii-pancreatic-cancer-trial 2024-12-18T05:28:13+00:00 weekly 0.7 https://trial.medpath.com/news/7819f0ce3a79ab56/oneoncology-cmo-emphasizes-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-12-18T04:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/5466272edbc6f7e7/oncology-leaders-highlight-growing-challenges-in-managing-cancer-treatment-data 2024-12-18T04:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/6db6471f08ac3c2d/ira-implementation-reshapes-cancer-drug-development-and-access-landscape 2024-12-18T04:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/66a117de5fd5488d/european-commission-grants-orphan-medicinal-product-designation-to-agios-mitapivat-for-sickle-cell-disease 2024-12-18T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee444a8119380020/merck-enters-obesity-market-with-112m-deal-for-hansoh-s-oral-glp-1-drug 2024-12-18T03:59:34+00:00 weekly 0.7 https://trial.medpath.com/news/048f79397a473746/clinical-trial-evolution-in-2025-strengthening-site-patient-relationships-through-technology 2024-12-18T03:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/85633997f8d2dddb/lipocine-inc-filed-sec-form-8-k-other-events-financial-statements-and-exhibits 2024-12-18T02:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/bbe0c52414c03c0b/study-shows-resistance-to-paxlovid-is-uncommon-cidrap 2024-12-18T02:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/06682068e496d7cd/eyedna-therapeutics-receives-fda-rare-pediatric-disease-designation-for-hora-pde6b 2024-12-18T00:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/e8c6bdd8494362d1/alzamend-neuro-to-present-non-clinical-data-on-al001-at-society-of-toxicology-2025 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b099a062b036809/medera-s-novoheart-partners-with-curi-bio-to-revolutionize-human-based-cardiac-drug-screening 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0acfbd1bf22590a6/retina-top-items-in-ophthalmology-for-2024 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/93b507070027e018/percheron-therapeutics-reports-resuls-from-phase-iib-study-of-avicursen 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ae4c46b78642174/noema-pharma-appoints-volker-knappertz-m-d-as-executive-vice-president-of-research-development 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/10d160abfc409556/startup-siteone-secures-100m-to-forge-ahead-with-novel-non-opioid-pain-meds 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1f60cc51a12e8996/fda-grants-breakthrough-therapy-designation-to-gilead-s-trodelvy-for-lung-cancer-treatment 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2873ccaa78530e66/ucsf-led-study-advances-understanding-and-treatment-of-hidradenitis-suppurativa 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4867079f37cd9d3b/alpha-tau-to-present-new-data-at-2025-asco-gi-symposium-and-host-r-d-update-day 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7aeef8b1d211f4a5/sanofi-shares-surge-following-positive-mid-stage-study-results 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7a9df936a7b9ec4a/teva-and-sanofi-jump-on-experimental-bowel-disease-drug-success-yahoo-finance 2024-12-17T21:49:01+00:00 weekly 0.7 https://trial.medpath.com/news/46f4c6b545e1d236/research-spotlight-pancreatic-cancer-a-look-back-at-2024 2024-12-17T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/e31e1aadb96eacc6/structure-therapeutics-unveils-breakthrough-oral-obesity-drug-first-in-class-amylin 2024-12-17T21:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/19b422dbcb22b970/partnership-advances-targeted-therapies-for-blood-cancers-newswise 2024-12-17T20:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/7279b3529173d222/asco-reading-room-sc-vs-iv-trastuzumab-pertuzumab-a-time-and-motion-substudy-of 2024-12-17T20:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/5886d1a0d8ac8796/ideaya-announces-idmc-recommendation-of-move-forward-dose-in-part-2a-of-pr-newswire 2024-12-17T20:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/0b47b295f6c2dcdc/177lu-dotatate-is-a-viable-treatment-in-meningioma-targeted-oncology 2024-12-17T20:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/ced6cc4ab118130e/pulmonary-sarcoidosis-treatment-efzofitimod-phase-3-trial-to-go-on 2024-12-17T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/e7f88f4c5e20b838/precision-treatment-for-alzheimer-s-disease-reduces-phosphorylated-tau-mdlinx 2024-12-17T19:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/141e95ce75c4a2fc/ondine-commencing-us-phase-3-clinical-trial-webdisclosure 2024-12-17T19:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/72c22fba3db66cb6/biocardia-launches-revolutionary-morph-dna-steerable-introducer-advances-stock-titan 2024-12-17T19:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/bf932cc77dcf4a58/does-medical-cannabis-have-physical-mental-health-risks-rutgers-health-kicks-off-study 2024-12-17T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/78527ad83bccbe03/study-supports-role-of-ctdna-in-predicting-outcomes-in-hr-early-breast-cancer 2024-12-17T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/276a26c172a4800f/adrienne-waks-on-margot-tbcrc052-phase-ii-trial-in-her2-positive-breast-cancer 2024-12-17T18:55:31+00:00 weekly 0.7 https://trial.medpath.com/news/a1878a405b31e577/analysts-tell-moderna-investors-to-hold-after-2024-s-steep-drop-biospace 2024-12-17T17:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/d5865f6d307329a8/merck-targets-2025-rsv-season-with-antibody-now-under-fda-review-biopharma-dive 2024-12-17T17:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/d9a72c0996a5deba/neural-stem-cell-transplants-show-promise-for-spinal-injuries-neuroscience-news 2024-12-17T17:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/cd2f63880394e472/top-cancer-treatment-advances-at-msk-in-2024 2024-12-17T16:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/5d80040c151da0f7/muscle-stem-cell-therapy-offers-hope-for-duchenne-patients-technology-networks 2024-12-17T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/d605ae5d359d3540/kidney-patients-interested-and-anxious-on-xenotransplantation-clinical-trials 2024-12-17T16:50:29+00:00 weekly 0.7 https://trial.medpath.com/news/d8c9cfd206253bb0/dc-circuit-affirms-fda-s-fast-track-denial-of-vanda-stomach-drug-bloomberg-law-news 2024-12-17T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/098683687fd8c516/immune-suppressing-drug-does-not-improve-covid-19-recovery-study-vumc-news 2024-12-17T15:54:10+00:00 weekly 0.7 https://trial.medpath.com/news/d8905458536b6289/granules-pharmaceuticals-gains-u-s-fda-approval-for-lisdexamfetamine-dimesylate 2024-12-17T15:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/858350478882c83b/fda-issues-complete-response-letter-to-subcutaneous-amivantamab-bla-in-egfr-nsclc 2024-12-17T15:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/b93d42c0c646599f/u-s-woman-living-healthy-with-kidney-sourced-from-pig 2024-12-17T15:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/9c9e42e107993ac5/camizestrant-outperforms-fulvestrant-in-er-her2-breast-cancer 2024-12-17T15:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/756f8fd8f6bcc981/menin-inhibitor-clinical-trial-puts-pediatric-leukemia-patient-in-remission 2024-12-17T15:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/48e71d88a97536ff/parkinson-s-drug-comes-to-market-with-help-of-renowned-university-of-kansas 2024-12-17T14:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/80acf424618826b0/arcturus-shares-maintain-buy-rating-as-ema-nods-to-covid-19-vaccine-investing-com 2024-12-17T14:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/e41b6220f2fed64e/fda-approves-orphan-drug-designation-for-jaguar-health-s-crofelemer-for-treatment-of 2024-12-17T14:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/81f4a7c51426567a/sonnet-biotherapeutics-holdings-inc-reports-significant-clinical-progress-and-financial-updates-for-fiscal-year-2024 2024-12-17T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/32ccded9131fd10c/psyence-biomed-highlights-recent-progress-on-active-phase-iib-clinical-trial 2024-12-17T13:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/47a829792e6aedde/fda-grants-breakthrough-status-to-gilead-s-lung-cancer-drug-investing-com 2024-12-17T13:42:31+00:00 weekly 0.7 https://trial.medpath.com/news/0e0b7c46fc0fbc6a/fda-grants-fast-track-designation-to-lipocine-for-lpcn-1148-as-a-treatment-for-pr-newswire 2024-12-17T13:32:25+00:00 weekly 0.7 https://trial.medpath.com/news/f8d51134893dd4b8/indapta-therapeutics-secures-22-5-million-to-advance-clinical-trials-of-innovative-cancer 2024-12-17T13:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/48b29d8162092b77/biomea-fusion-s-diabetes-drug-shows-breakthrough-results-in-phase-ii-trial-stock-titan 2024-12-17T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/da7a43b71ae1ed6c/abbott-announces-first-in-world-leadless-pacing-procedures-in-the-left-bundle-branch 2024-12-17T13:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/fe7e687745fade63/mediwound-to-host-virtual-key-opinion-leader-event-to-globenewswire 2024-12-17T13:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/6b4e0072df95f69f/glyconex-announces-first-patient-dosed-in-phase-3-clinical-trial-for-denosumab-biosimilar 2024-12-17T12:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/1a2700f3cc340822/j-j-s-fda-bid-for-subcutaneous-rybrevant-falls-short-biospace 2024-12-17T12:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/1e57c88a76b763dc/eylea-hd-r-aflibercept-injection-8-mg-phase-3-trial-meets-globenewswire 2024-12-17T12:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/4e59d96503954b36/teen-substance-use-hits-historic-lows-mtf-survey-shows-continued-post-pandemic-decline 2024-12-17T12:19:10+00:00 weekly 0.7 https://trial.medpath.com/news/31308e1e73ea9ed3/essa-pharma-halts-key-cancer-drug-trials-initiates-strategic-review-amid-clinical-setback 2024-12-17T12:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/6cfbf0426c03957a/icymi-highlights-from-ims-2024-american-journal-of-managed-care 2024-12-17T12:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/28e35d05f506c500/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-biospace 2024-12-17T11:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/d25b40bf300f0280/biohaven-ltd-s-strategic-advancements-and-pipeline-strengthen-buy-rating 2024-12-17T11:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/075d5890f3fe0662/what-s-driving-biomea-fusion-stock-soars-25-markets-insider 2024-12-17T10:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/fc04d3e1e616e614/ou-health-sciences-leads-clinical-trial-of-device-designed-to-induce-ovulation-in-women-with-pcos 2024-12-17T10:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/ad7cad9428cf9c03/corcept-therapeutics-cushing-s-syndrome-therapy-shows-promise-in-phase-iii-trial-yahoo 2024-12-17T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/b148ad5d25eadaf6/nuclear-isotopes-emerge-as-promising-tool-in-cancer-clinical-trials-despite-production-challenges 2024-12-17T10:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/0be702d64347a0d6/esocap-publishes-positive-phase-ii-results-for-eso-101-in-treating-eosinophilic-esophagitis 2024-12-17T10:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/25dc2a763cc889ac/mytomorrows-enhances-clinical-trial-platform-with-isrctn-integration-and-ai-capabilities 2024-12-17T10:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/fdef9fbf5028a71b/quadruplet-therapy-and-mrd-monitoring-show-promise-in-newly-diagnosed-multiple-myeloma-treatment 2024-12-17T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e246c3ead483f896/exegi-pharma-reports-positive-topline-results-in-exe-346-prof-phase-1b-study 2024-12-17T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/39da87c225e9a71b/senders-pediatrics-seeks-young-participants-for-epstein-barr-virus-vaccine-clinical-trial 2024-12-17T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc7c2ef627d7c7aa/butantan-institute-seeks-anvisa-approval-for-single-dose-dengue-vaccine 2024-12-17T08:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/245773f9ab419a5d/digital-training-tool-developed-to-enhance-biosimilar-switch-communication-between-prescribers-and-patients 2024-12-17T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ae353ec9acbba14/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-advanced-renal-cell-carcinoma-urotoday 2024-12-17T08:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/87b386e5faf4d12d/uncommon-cures-and-carexso-partner-to-expand-orphan-drug-clinical-trials-in-the-middle-east 2024-12-17T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/8eb1951c299db4de/how-j-j-navigated-regulatory-approval-for-a-drug-to-watch-clarivate 2024-12-17T08:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/2cc2e800848b313b/fda-denies-full-approval-for-andexxa-following-dosing-uncertainties 2024-12-17T07:13:46+00:00 weekly 0.7 https://trial.medpath.com/news/9c13f3eaed7da98f/nurix-therapeutics-btk-degrader-shows-promise-in-clinical-trials 2024-12-17T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/05e37c5a5fec388b/neurogene-s-gene-therapy-shows-promise-for-rett-syndrome-amid-clinical-and-market-risks 2024-12-17T04:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd6ea7a5cc5f6c02/ascendis-pharma-s-promising-growth-prospects-buy-rating-backed-by-positive-clinical-results 2024-12-17T04:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/5484f21582887f8f/health-check-clinical-trials-don-t-sleigh-down-for-the-silly-season-stockhead 2024-12-17T01:49:48+00:00 weekly 0.7 https://trial.medpath.com/news/7e49874f9d710f35/bavarian-nordic-partners-with-serum-institute-of-india-for-global-mpox-vaccine-manufacturing 2024-12-17T01:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/ec0b6e0172f64f1e/are-you-over-18-generally-healthy-and-assigned-male-at-birth-the-reporter-uab 2024-12-17T01:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/83d73eba696ae412/the-link-between-hearing-loss-and-cognitive-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f4b4e27c548ba4a7/top-5-most-read-breast-cancer-articles-of-2024-highlight-advances-in-research-and-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ded07197e7152151/biper-therapeutics-secures-eur800000-in-bridge-funding-for-gastrointestinal-cancer-treatment-development 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/203c7b1484ac9cd2/guangshengtang-s-innovative-hepatitis-b-drug-included-in-breakthrough-therapy-list 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b7e263630fa2112/surgical-intervention-may-improve-survival-in-young-patients-with-breast-cancer 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ac08730ff254d543/immuneering-to-present-data-from-three-arms-of-its-ongoing-phase-2a-trial-of-imm-1-104-in-early-january-2025 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e8997baff67e6bf9/fresenius-kabi-launches-epinephrine-injection-usp-expanding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0298e693c5414b1/biomea-fusion-s-diabetes-drug-study-shows-positive-results-despite-stock-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/884fff71d26f192d/lipocine-inc-advances-in-metabolic-and-endocrine-disorders-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3dde2b90b35fad88/cardiofocus-announces-first-patients-treated-with-optishottm-pulsed-field-ablation-system 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/360936cbbf3eb537/affimed-reports-positive-clinical-update-on-afm24-atezolizumab-combination-therapy-in-non-small-cell-lung-cancer-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f7e20869e4ed748b/large-clinical-study-finds-home-based-virtual-reality-device-creates-greater-relief-for-high-impact-chronic-pain-patients 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c38dd3507e983cd/fda-gives-crl-to-j-j-s-bla-for-subcutaneous-rybrevant-in-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/64dce108f2dafcc6/novavax-vaccine-insights-on-pregnancy-and-breastfeeding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/07067097b044892a/sagimet-biosciences-up-30-on-strong-clinical-stage-data-mugglehead-magazine 2024-12-16T23:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/a0e343e5c093f92c/suo-2024-update-on-neoadjuvant-therapy-trials-in-rcc 2024-12-16T23:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/c902cb1f12486a2e/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-in-3l-mcrc 2024-12-16T23:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/1d33a8614961d6ad/biomea-fusion-to-host-conference-call-to-announce-topline-results-from-phase-ii-covalent-111 2024-12-16T23:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/97e812fc43909ca1/biomea-fusion-to-host-conference-call-to-announce-topline-globenewswire 2024-12-16T23:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/14a32fa13f64e54d/purpose-beyond-a-cure-advancing-hodgkin-lymphoma-treatment-uf-health 2024-12-16T22:50:40+00:00 weekly 0.7 https://trial.medpath.com/news/74f6d688d95faaa4/prevail-therapeutics-seeking-to-bring-gene-therapy-pr001-to-parkinson-disease-cgtlive-r 2024-12-16T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/f01c1218ae842651/first-patient-enrolled-receive-kimmtrak-in-phase-3-uveal-melanoma-trial-cure-today 2024-12-16T22:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/7181cb5b3a3f04c5/lehigh-valley-health-network-only-in-region-to-participate-in-drug-coated-balloon-clinical-trial 2024-12-16T22:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/521f99bb9d9fb19c/briacell-therapeutics-corp-sec-10-q-report-tradingview 2024-12-16T22:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/61bcb88a41bf5cea/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs 2024-12-16T21:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/47334db3696e7adf/knight-therapeutics-announces-filing-of-new-drug-submission-for-qelbree-r-viloxazine-in-canada 2024-12-16T21:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/a34219b4db24bf73/contineum-therapeutics-initiates-patient-dosing-in-phase-1b-pet-trial 2024-12-16T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf0a6eb6f72b267a/study-explores-whether-cbd-can-reduce-scan-related-anxiety-in-patients-with-advanced 2024-12-16T20:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/02ac59750e529062/biocardia-s-swot-analysis-cell-therapy-stock-faces-pivotal-trial-phase-investing-com 2024-12-16T20:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/53bbdc194d52a140/national-trial-explores-light-therapy-for-parkinson-s-disease 2024-12-16T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/019a7b715d3a92a4/q32-bio-pushes-back-phase-2-trial-of-adx-097-in-aav-patients-anca-vasculitis-news 2024-12-16T19:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/a58f896d412fa895/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-pr-newswire 2024-12-16T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/fe698c6cf251fa77/tracer-to-diagnose-parkinson-s-via-pet-scans-moving-into-clinical-trial 2024-12-16T18:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/99a993ca10c9a00d/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb 2024-12-16T18:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/6680f5d8808f3009/mark-humayun-md-phd-discusses-advance-stem-cell-derived-therapies-for-dry-amd 2024-12-16T17:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/8e5cd5a7a3650de9/usf-health-launches-state-funded-hyperbaric-oxygen-therapy-trial-with-first-patient 2024-12-16T16:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/5b236993fe76b2d5/reviva-announces-prel-topline-ole-data-of-phase-3-recover-study-of-brilaroxazine-in 2024-12-16T16:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/50a0c03768d0c30c/efficacy-of-sildenafil-cream-for-fsad-maintained-across-patient-subgroups-urology-times 2024-12-16T16:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/9133622865364142/lib-therapeutics-submits-a-biologic-license-application-to-fda-for-lerodalcibep-for-biospace 2024-12-16T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/ef32cedef5c9c611/why-the-investor-craze-for-ozempic-and-rival-weight-loss-drugs-may-resume-next-year 2024-12-16T15:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/65f6b58bb1d120a2/blood-test-may-reduce-unnecessary-prostate-cancer-biopsies-news-center 2024-12-16T15:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/a962214f4d59db87/3-closely-watched-drugs-that-failed-in-the-clinic-pharmavoice 2024-12-16T15:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/f40060d6692f4561/neurocrine-jumps-after-snagging-fda-approval-for-a-first-in-decades-drug-yahoo 2024-12-16T15:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/037f83bfc696bd0f/arcutis-submits-snda-for-roflumilast-cream-0-05-to-fda-for-patients-ages-2-to-5-with 2024-12-16T15:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/0dee7c2ba2024775/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-rekambys-the-first-and 2024-12-16T14:57:03+00:00 weekly 0.7 https://trial.medpath.com/news/c797fa3d2fcb5df1/genprex-s-reqorsa-advances-to-phase-2-after-successful-safety-trial-in-lung-cancer-treatment 2024-12-16T14:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/3ad8afae9cb6be98/dermata-receives-approval-from-fda-for-the-proprietary-name-xyngari-tm 2024-12-16T14:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/ac51c6e9c81c6505/novel-dll3-targeted-bites-and-b7-h3-adcs-show-promise-in-extensive-stage-sclc-treatment 2024-12-16T14:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/8d1e7d492c7fb64c/new-insights-trial-of-transcontm-hgh-lonapegsomatropin-in-globenewswire 2024-12-16T14:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/60b9a25c8f0e4498/sifi-provides-updates-on-the-uk-and-us-regulatory-pathways-for-akantior-r-in-the-biospace 2024-12-16T13:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/276e899609673d15/tharimmune-announces-phase-2-study-plan-for-th104-in-patients-with-moderate-to-severe 2024-12-16T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/news/1ea5a228763f456c/maia-biotech-secures-fda-rare-pediatric-disease-status-for-novel-brain-cancer-drug 2024-12-16T13:52:22+00:00 weekly 0.7 https://trial.medpath.com/news/ad35d0161a90a000/beigene-explains-the-landscape-of-oncology-trials-in-brazil-clinical-leader 2024-12-16T13:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/395970866268a1d5/beta-blockers-associated-with-delayed-onset-and-decreased-progression-of-huntington-s-disease 2024-12-16T13:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/ba440a9596e93be3/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-biospace 2024-12-16T13:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/8583b7fffd1ab44a/first-in-human-study-demonstrates-the-potential-of-the-reprieve-system-in-patients-with 2024-12-16T13:45:13+00:00 weekly 0.7 https://trial.medpath.com/news/4d018e0369851c04/histosonics-is-expanding-to-treat-pancreatic-tumors-massdevice 2024-12-16T13:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/e8b7e75135ee965e/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-gsk 2024-12-16T13:15:44+00:00 weekly 0.7 https://trial.medpath.com/news/9843a31184de5739/puretech-s-breakthrough-ipf-drug-shows-81-superior-efficacy-in-phase-2b-trial-results 2024-12-16T13:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/5ef14bcd1b2a7cc1/goldman-sachs-lifts-neurocrine-bio-shares-target-buy-rating-on-fda-approval 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/c447e79ed076ab48/pepgen-announces-clinical-hold-in-the-u-s-on-ind-application-to-initiate-connect2 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/9734ee860ce7eeee/windtree-announces-istaroxime-presentation-by-cardiogenic-globenewswire 2024-12-16T13:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/302291f549f4b9b3/dare-bioscience-announces-phase-3-plans-for-sildenafil-globenewswire 2024-12-16T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/8b75b5829a886036/senti-bio-announces-first-patient-dosed-in-clinical-trial 2024-12-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/b52250619f7ad523/scisparc-advances-11-6m-pharma-portfolio-spin-off-deal-with-miza-ventures-retaining 2024-12-16T12:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/1f67fa7b83012ac1/china-approves-merck-s-keytruda-to-treat-patients-with-resectable-stage-ii-iiia-or-iiib-nsclc 2024-12-16T12:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/5d8fd7ff14df9194/fda-approves-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-morningstar 2024-12-16T12:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/3cb5566f3a80d07c/atsena-therapeutics-announces-dosing-completed-in-part-a-of-globenewswire 2024-12-16T12:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/8418db086af10244/roche-discontinues-hemophilia-a-gene-therapy-development-shifts-focus-to-enhanced-function-fviii-variant 2024-12-16T12:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/deca75d09fdfab1a/foghorn-therapeutics-provides-update-on-fhd-286-clinical-development-program-and 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/f49639b0056f1b21/vectory-strengthens-leadership-team-with-appointment-of-jim-scibetta-as-new-ceo 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/a0cc592447be5a26/2024-key-insights-skin-cancer-dermatology-times 2024-12-16T12:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/7193eb06de50c1e5/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents 2024-12-16T12:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/be918fc7562b1e64/fluid-biomed-closes-27-million-usd-series-a-to-fund-expanded-human-clinical-studies 2024-12-16T12:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/ee10024a50885085/caplin-steriles-receives-fda-approval-for-generic-difluprednate-eye-drops-ndtv-profit 2024-12-16T11:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/767c38ed58754704/astrazeneca-s-oncology-innovations-and-financial-growth-prospects 2024-12-16T11:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b3d6099181e0e54/a-10-year-old-parker-girl-s-disease-is-one-in-a-million-the-colorado-sun 2024-12-16T11:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/9c29c139b7dfe1d5/mannkind-s-inhaled-insulin-shows-promise-in-pivotal-pediatric-trial-eyes-fda-submission 2024-12-16T11:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/36e4b71f46e7e7be/study-supports-tamoxifen-for-dcis-early-breast-cancers 2024-12-16T11:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/edaa7eb1fda99153/edgewise-therapeutics-announces-positive-topline-results-from-the-canyon-phase-2 2024-12-16T11:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/7c35a45a922ec7df/medivir-s-ceo-to-biostock-the-ind-approval-is-a-very-important-milestone-cision-news 2024-12-16T10:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/2f03a5be0936fbaf/true-you-weight-loss-announces-two-clinical-trials-exploring-groundbreaking-non 2024-12-16T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/affa9f0c975c9607/sinovac-launches-groundbreaking-phase-3-trial-for-first-global-multivalent-hfmd-vaccine 2024-12-16T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/11e2e31ddc2a8b58/incyclix-bio-reports-outcomes-from-breast-cancer-therapy-trial 2024-12-16T10:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/29e12a8d5fcc5c6d/new-alzheimer-s-treatment-option-now-available-in-lafayette 2024-12-16T10:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/b062cb188dcc2f8b/accord-healthcare-is-granted-marketing-authorisation-for-imuldosa-r-ustekinumab 2024-12-16T10:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/244cc992ededbcaa/exercise-during-cancer-treatment-significantly-improves-survival-rates-in-breast-cancer-patients-roswell-park-study-shows 2024-12-16T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3226a30ef5d7f197/danish-medicines-agency-seeks-eu-review-of-ozempic-over-risk-of-rare-vision-loss 2024-12-16T09:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/6851cf65049ab98f/gsk-receives-three-positive-regulatory-updates-on-cancer-products-shares-magazine 2024-12-16T09:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/b828b65a0a3d2cc7/jazz-pharmaceuticals-ceo-bruce-cozadd-announces-retirement-after-15-year-tenure 2024-12-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/672949bece1bf430/assertio-therapeutics-receives-buy-rating-following-positive-clinical-trial-results 2024-12-16T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/b08a545af3e20776/world-economic-forum-report-generative-ai-set-to-transform-clinical-trial-development 2024-12-16T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/756109816aacfd89/december-16-2024-study-snapshot-and-updated-ethics-documentation-available-for-i 2024-12-16T09:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/1146fee38a027280/medicare-and-medicaid-see-dramatic-rise-in-rituximab-biosimilar-adoption-achieving-60-market-share-by-2022 2024-12-16T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/94cf6a2baf41047d/shb-raises-target-price-for-egetis-therapeutics-to-sek-16-9-reiterates-buy 2024-12-16T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/news/ed8cc76058e59a74/gh-research-awaits-topline-data-from-gh001-in-treatment-resistant-depression-trial 2024-12-16T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/86a777009b086258/study-reveals-significant-sleep-disruption-among-parents-of-children-with-atopic-dermatitis 2024-12-16T08:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/122ef7da901ef4c4/gerresheimer-fda-grants-tentative-approval-of-sq-innovation-s-lasix-r-onyu-eqs-news 2024-12-16T08:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/a29cd96418a56e34/inventiva-secures-eur21-4-million-and-completes-the-first-globenewswire 2024-12-16T07:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/fc4ee68473876c59/exact-therapeutics-announces-fda-clearance-of-ind-for-enact-a-phase-2-trial-in 2024-12-16T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/79ee231b8d454ef2/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-ema-priority-medicines 2024-12-16T07:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/08fe0bf27f16a180/kraig-biocraft-doubles-spider-silk-gene-complexity-advancing-commercial-production-of-high-performance-biomaterials 2024-12-16T06:45:20+00:00 weekly 0.7 https://trial.medpath.com/news/2e4f9039c2329303/beigene-acquires-global-rights-to-dualitybio-s-adc-in-milestone-for-nona-biosciences-collaboration-network 2024-12-16T06:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/366089de6f584297/relief-therapeutics-announces-final-readout-of-pku-golike-clinical-trial-stock-titan 2024-12-16T06:25:19+00:00 weekly 0.7 https://trial.medpath.com/news/0186b99e2298c4ac/cultural-understanding-key-to-addressing-ovarian-cancer-disparities-among-pacific-islanders-study-finds 2024-12-16T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0d22882a3b8f0e9e/car-t-cell-therapy-for-autoimmune-disease-gains-traction-drug-discovery-news 2024-12-16T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/fea34f47372a4cec/wockhardt-rises-10-after-antibiotic-zaynich-undergoing-clinical-trials-facilitates-in-a-liver-transplant 2024-12-16T04:32:51+00:00 weekly 0.7 https://trial.medpath.com/news/761e0bb5d122df33/wockhardt-shares-add-to-their-220-gain-for-2024-with-another-10-surge-explained 2024-12-16T04:32:47+00:00 weekly 0.7 https://trial.medpath.com/news/6960df490d5b5e54/fda-approves-multiple-breakthrough-therapies-crenessity-for-cah-unloxcyt-for-skin-cancer 2024-12-16T03:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1c4bf1f91aca8b5/global-clinical-trial-landscape-shows-asia-pacific-leading-sclc-research-with-over-1200-studies-since-2019 2024-12-16T03:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/702269c25a71e850/hiro-forges-strategic-partnership-with-cha-university-bundang-medical-center-in-south-korea 2024-12-16T03:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/3a6c410a9bd86390/25-years-of-cgm-innovation-major-advances-mark-2024-as-breakthrough-year-for-glucose-monitoring 2024-12-16T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/63a2e1a62c841f8d/ai-powered-ecg-analysis-set-to-transform-pharmaceutical-drug-development-and-clinical-trials 2024-12-16T02:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/a95827ac7e145b04/european-chmp-recommends-approval-for-four-celltrion-biosimilars-businesskorea 2024-12-16T02:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/2c0e528656d9a547/pharming-announces-public-cash-offer-to-the-shareholders-of-abliva-ab-stock-titan 2024-12-16T01:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/8d883615d60a027c/addition-of-shr-1701-to-first-line-capecitabine-and-oxaliplatin-xelox-plus-bevacizumab 2024-12-16T01:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/6b14738df2aa804a/noninvasive-early-identification-of-durable-clinical-benefit-from-immune-checkpoint-inhibition 2024-12-16T01:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/c3002e39e014c17c/top-5-most-read-all-aml-articles-in-2024 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79de1834decf06b8/new-study-finds-psychedelic-drug-can-help-ease-depression-among-healthcare-workers 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c787a802eb3cbe77/success-with-adjuvant-ribociclib-leads-to-fda-approval-in 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/24708c1fc8e50790/hs-20093-b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d9f558ef764f209d/eo-3021-demonstrates-effectiveness-in-cldn18-2-expressing-cancer-models 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8acf3939983a9b75/percheron-therapeutics-halts-trading-ahead-of-trial-results 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d094b1831117afd6/beckley-psytech-announces-positive-results-for-ele-101-in-depression-trial 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e129ea8eb7276b8/trial-investigating-v940-and-pembrolizumab-for-squamous-cell-skin-cancer-treatment 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7e612fdc0f67b0c/heartsciences-reports-second-quarter-fiscal-2025-financial-results-and-business-update 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d9a766d8b9e5d274/invios-to-showcase-oncology-pipeline-progress-at-jp-morgan-week-2025 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b91d55137a48bd9f/here-are-5-asx-biotechs-expecting-clinical-trial-results-in-the-next-few-months 2024-12-15T23:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/c07366d2ffcd8488/tiny-robots-thinner-than-a-human-hair-could-help-fight-cancer-tumours-reveals-study 2024-12-15T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ae926bb4c4fb621/mixed-signals-from-trials-of-perioperative-neoadjuvant-immunotherapy-for-early-tnbc 2024-12-15T22:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/ee1661738220e17c/protagonist-therapeutics-swot-analysis-stock-poised-for-growth-amid-clinical-trials 2024-12-15T21:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/32880d0164afc4de/professor-kim-gun-ho-receives-fda-approval-for-ocucool-eye-anesthesia-technology 2024-12-15T21:18:18+00:00 weekly 0.7 https://trial.medpath.com/news/e994f1995b48f91d/advancing-epilepsy-treatment-with-novel-approaches-and-predictive-technologies-neurologylive 2024-12-15T21:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/958ffcd2d1211ac9/abbvie-and-neomorph-forge-1-64-billion-molecular-glue-degrader-partnership-for-oncology-and-immunology 2024-12-15T21:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/3188a1571a8c28ff/cwr-expands-clinical-trials-to-tackle-high-disease-burden-in-nigeria-others 2024-12-15T20:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/33a4dd962b22f31e/2nd-phase-transgenic-silkworm-trials-focus-on-virus-resistance-times-of-india 2024-12-15T19:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/833b15a7350c453a/bristol-myers-squibb-and-2seventy-bio-s-car-t-ide-cel-effects-responses-in-cns-involved 2024-12-15T17:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/057c2a0702ab4449/lipigon-pharmaceuticals-appoints-new-ceo-marketscreener 2024-12-15T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/af4cac2024e3fc20/intas-pharmaceutical-gets-cdsco-panel-nod-to-study-aflibercept-solution-for-injection-40 2024-12-15T16:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/5d5a983dfc52b16c/evaluating-belzutifan-for-clear-cell-renal-cell-carcinoma-treatment-targeted-oncology 2024-12-15T16:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/d3b185e36d37e5cb/stockwatch-q32-shares-crater-85-as-investors-analysts-sour-on-trial-results 2024-12-15T16:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/29df63c24a0b5237/outpatient-lymphodepletion-prior-to-brexu-cel-is-safe-effective-in-b-all-mcl 2024-12-15T15:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/191cc2b5240e5517/commentary-kudos-criticism-mark-california-stem-cell-agency-as-it-turns-20-stocktonia 2024-12-15T15:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/956e8f6d0bbfa01c/promising-combination-therapy-could-improve-liver-cancer-outcomes-news-medical 2024-12-15T14:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/1c56173d3f1e4223/is-pfizer-a-millionaire-maker-yahoo-finance 2024-12-15T14:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/c5be96393b18fa69/weight-loss-linked-to-lower-inflammatory-markers-in-women-with-breast-cancer-healio 2024-12-15T14:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/677b6128ff73aeff/francoise-bernaudin-md-on-allosct-superiority-over-soc-for-sickle-cell-anemia 2024-12-15T14:23:57+00:00 weekly 0.7 https://trial.medpath.com/news/f36dfaa7083296e5/mind-medicine-s-swot-analysis-stock-poised-for-growth-in-anxiety-treatment-investing-com 2024-12-15T14:12:35+00:00 weekly 0.7 https://trial.medpath.com/news/f0165efb66907b02/investigational-hepatitis-d-therapy-well-tolerated-safe-for-chronic-disease-at-week-48 2024-12-15T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/765562a154fee05f/gan-lee-pharmaceutical-rose-0-68-this-week-and-the-biological-products-sector-fell-1-58 2024-12-15T12:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/26b4424d493e4972/2-weight-loss-stocks-that-are-screaming-buys-in-december 2024-12-15T12:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/57d0f5b9f6b10df7/replimune-s-melanoma-treatment-nears-key-milestones 2024-12-15T11:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/800c7715da3bb021/artiva-biotherapeutics-s-swot-analysis-nk-cell-therapy-stock-poised-for-autoimmune-breakthrough 2024-12-15T09:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/a223d2ea03867fe7/clinical-trial-opportunity-for-erectile-dysfunction-treatment 2024-12-15T09:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/47c10b6c64ca3575/breakthrough-in-gene-therapy-for-haemophilia-a-at-christian-medical-college-vellore 2024-12-15T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ce093646c7ea5b8/yifang-biopharma-on-december-4-it-was-surveyed-by-institutions-including-well-known 2024-12-15T05:53:32+00:00 weekly 0.7 https://trial.medpath.com/news/37d3b9d267c31d08/ponatinib-related-toxicity-management-in-all-cml-improves-over-time-cancer-network 2024-12-15T05:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/186decee452b31a2/fate-therapeutics-advances-in-autoimmune-disease-treatment-with-promising-cell-therapy-programs 2024-12-15T04:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/18b752b32afa38a3/behind-the-leap-012-trial-of-lenvatinib-pembrolizumab-and-tace-in-hcc 2024-12-15T04:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/329b8e1310383826/key-highlights-from-the-american-society-of-hematology-meeting-and-regulatory-updates 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e0675ddb352e66f/inovio-s-swot-analysis-biotech-stock-faces-manufacturing-hurdles-amid-pipeline-progress 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da605e125d95d6a1/gdf-15-inhibitors-show-promise-against-hard-to-treat-tumors-in-clinical-trial 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f5263b60ee77a349/oppenheimer-predicts-significant-growth-for-sagimet-and-y-mabs-therapeutics 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f9fa571dc2bd96f/adjuvant-anthracycline-plus-taxane-based-chemotherapy-regimen-improves-survival-in-high 2024-12-14T23:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/b1903bf8a664ee12/psilocybin-industry-will-focus-on-fine-tuning-first-in-the-nation-program-in-2025-opb 2024-12-14T22:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/cf0835f2b21cb15f/russia-announces-free-personalized-cancer-vaccine-the-pinnacle-gazette 2024-12-14T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/f07d29157e87ca72/aaron-nagial-md-phd-gives-interview-on-the-impact-of-retinal-gene-therapy-procedure 2024-12-14T20:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/40c17ba077333da9/a-low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate-cancer-growth-ucla-study-finds 2024-12-14T20:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/bf3981824babf70b/jennifer-b-green-md-implementation-of-evidence-based-therapies-for-t2d-hcplive 2024-12-14T19:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/5945c9281a331194/sensome-data-supports-clot-sensing-guidewire-massdevice 2024-12-14T18:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/e2bc672d2080465f/japanese-researchers-test-pioneering-drug-to-regrow-teeth-medical-xpress 2024-12-14T18:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/89b131cc9ae3a9d7/kura-oncology-s-swot-analysis-ziftomenib-s-promise-drives-stock-outlook-investing-com 2024-12-14T17:23:04+00:00 weekly 0.7 https://trial.medpath.com/news/53e217121c13a315/letter-to-the-fda-commissioner-requesting-an-investigation-of-the-conduct-of-alzheimer-s 2024-12-14T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/c4c7a1c639044186/soxrc-regimen-improves-responses-versus-chemo-alone-in-advanced-gastric-cancers 2024-12-14T15:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/17f9b05cbc2282d8/novo-nordisk-s-ozempic-reportedly-linked-to-vision-loss-in-new-study-yahoo-finance 2024-12-14T14:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/39e1b5255e9c4513/curateq-biologics-receives-positive-opinion-for-biosimilar-zefylti-indian-pharma-post 2024-12-14T14:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/bc98951ba1dc1df8/lower-aldosterone-thresholds-linked-to-increased-hypertension-risk-in-landmark-breakthrough-study 2024-12-14T14:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/bca8a3e319532678/what-happened-in-optometry-this-week-december-9 2024-12-14T12:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/41b95d51c8ea9d78/phase-i-gynecological-cancer-data-sink-repare-shares-bioworld 2024-12-14T12:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/ca7b026f128a975c/new-research-highlights-potential-of-diabetes-medications-in-reducing-dementia-risk 2024-12-14T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/1981f0ed6ed73856/the-biggest-medical-breakthroughs-of-2024-gizmodo 2024-12-14T12:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/e981c044b06de4d4/astrazeneca-says-andexxa-will-not-convert-to-full-approval-quietly-reveals-complete-response 2024-12-14T11:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/7315597ac5457454/biontech-se-and-its-partner-oncoc4-inc-continue-enrollment-in-phase-3-trial-for-bnt316 2024-12-14T11:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/3eabe6cb88bb9241/enrollment-hits-75-for-phase-2b-clinical-trial-of-haduvio-for-ipf-pulmonary-fibrosis-news 2024-12-14T11:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/2febc2528ff2d7d2/rising-obesity-in-type-1-diabetes-patients-signals-need-for-new-cardiovascular-treatment-approaches 2024-12-14T10:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/1a15f3391e879426/real-world-data-and-ai-help-improve-ild-management-in-her2-breast-cancer 2024-12-14T09:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/7550456f9b87a80c/new-hpv-self-test-approach-could-enhance-cervical-cancer-screening-news-medical 2024-12-14T08:42:29+00:00 weekly 0.7 https://trial.medpath.com/news/4e35cff23eb2e6ad/cgtlive-r-s-weekly-rewind-december-13-2024 2024-12-14T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/6cbd547836d67e39/the-effect-of-acupuncture-intervention-on-chronic-musculoskeletal-pain-jpr-dove-medical-press 2024-12-14T07:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/8bb3513630dde96b/cg-oncology-positive-phase-3-outcome-could-lead-to-bla-of-cretostimogene 2024-12-14T07:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/8d4c7a3c5977acc3/ai-powered-mammography-analysis-shows-promise-for-long-term-breast-cancer-prevention 2024-12-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c7519f2a22f20a5/coa-2024-value-based-care-challenges-and-pbm-reform-take-center-stage-in-oncology 2024-12-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/713ff9c30ae90fa6/miller-school-spinoff-uses-rna-to-tackle-deadly-disease-inventum 2024-12-14T03:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/529501004d44ae1b/emerging-research-leveraging-technology-in-phase-i-clinical-trials-massbio 2024-12-14T02:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/3c6edd2c9ce3c418/study-confirms-semaglutide-link-to-increased-but-low-risk-of-naion-markets-insider 2024-12-14T02:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/83d96136461a1889/edesa-biotech-reports-fiscal-year-2024-results-stock-titan 2024-12-14T01:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/6e990e26daad8d3a/cancer-pipelines-shrink-as-incyte-iteos-cut-candidates-following-disappointing-data 2024-12-14T01:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/c932073dc6885edf/pharma-co-brass-face-investor-suit-over-drug-trial-probe-law360 2024-12-14T01:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/a3618ab3f7cc7cbb/new-leash-on-life-cape-coral-shelter-dog-beats-cancer-with-drug-being-tested-for-humans 2024-12-14T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/b08b9989c0fb243f/cosibelimab-approved-by-fda-for-metastatic-locally-advanced-cutaneous-squamous-cell 2024-12-14T00:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/f3e4762b0d3c9dac/fda-suspends-valneva-s-chikungunya-vaccine-license-following-severe-adverse-events-in-elderly-patients 2024-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b91f9827376972ca/checkpoint-therapeutics-gets-its-first-fda-approval-morningstar 2024-12-13T23:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/09252bf485fba840/fda-approves-crinecerfont-for-congenital-adrenal-hyperplasia-hcplive 2024-12-13T23:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/d426eb7d7ffac26b/mpox-vaccine-ready-for-clinical-trial-chinadaily-com-cn 2024-12-13T23:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/bc44976e19578a0d/viridian-therapeutics-to-webcast-veligrotug-phase-3-thrive-2-topline-results-yahoo-finance 2024-12-13T23:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/53e6d2463c58f414/press-release-service-brightpath-bio-and-cellistic-announces-process-development-and 2024-12-13T23:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/e6609ddf90d90b82/study-promising-drug-for-treating-rare-childhood-cancer-qna 2024-12-13T22:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/900082764974990d/maia-biotechnology-director-ramiro-guerrero-buys-99998-in-stock-investing-com 2024-12-13T22:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/8b43159f39eda1fb/supportive-care-helps-manage-aes-with-teclistamab-in-r-r-multiple-myeloma 2024-12-13T22:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/49d7fde2ee0cae1a/center-for-biostatistics-in-aids-research-cbar-2024-highlights 2024-12-13T22:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/5bfb2f7021c3068a/t-dxd-preserves-qol-neurological-function-in-her2-metastatic-breast-cancer 2024-12-13T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/news/7f5caaade313d877/helping-kids-with-cancer-speak-for-the-supportive-care-they-need 2024-12-13T21:17:13+00:00 weekly 0.7